1
|
Almog M, Musallam N, Wagner R, Epov L, Kaly L, Dor V, Kessel A. Cow's milk oral immunotherapy has differentially better long-term adherence than peanut or sesame. Ann Allergy Asthma Immunol 2024:S1081-1206(24)00241-2. [PMID: 38677475 DOI: 10.1016/j.anai.2024.04.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2023] [Revised: 04/13/2024] [Accepted: 04/16/2024] [Indexed: 04/29/2024]
Affiliation(s)
- Meital Almog
- Division of Allergy & Clinical Immunology, Bnai Zion Medical Center, Rappaport Faculty of Medicine, Technion, Haifa, Israel
| | - Nadira Musallam
- Division of Allergy & Clinical Immunology, Bnai Zion Medical Center, Rappaport Faculty of Medicine, Technion, Haifa, Israel
| | - Roni Wagner
- Division of Allergy & Clinical Immunology, Bnai Zion Medical Center, Rappaport Faculty of Medicine, Technion, Haifa, Israel
| | - Larisa Epov
- Division of Allergy & Clinical Immunology, Bnai Zion Medical Center, Rappaport Faculty of Medicine, Technion, Haifa, Israel
| | - Lisa Kaly
- Rheumatology Unit, Bnai Zion Medical Center, Rappaport Faculty of Medicine, Technion, Haifa, Israel
| | - Vika Dor
- Division of Allergy & Clinical Immunology, Bnai Zion Medical Center, Rappaport Faculty of Medicine, Technion, Haifa, Israel
| | - Aharon Kessel
- Division of Allergy & Clinical Immunology, Bnai Zion Medical Center, Rappaport Faculty of Medicine, Technion, Haifa, Israel.
| |
Collapse
|
2
|
Genizi J, Berger L, Mahajnah M, Shlonsky Y, Golan-Shany O, Romem A, Halevy A, Nathan K, Sharkia R, Zalan A, Kessel A, Cohen R. High CCL2 Levels Detected in CSF of Patients with Pediatric Pseudotumor Cerebri Syndrome. Children (Basel) 2023; 10:1122. [PMID: 37508619 PMCID: PMC10378220 DOI: 10.3390/children10071122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/21/2023] [Revised: 06/18/2023] [Accepted: 06/25/2023] [Indexed: 07/30/2023]
Abstract
Pseudotumor cerebri (PTC) is a disorder characterized by increased intracranial pressure in the absence of a structural lesion or other identifiable cause. Cytokines, which are involved in the regulation of immune responses and inflammation, have been implicated in the pathogenesis of PTC. In a prospective, cross-sectional study at three centers in Israel, we analyzed cerebrospinal fluid (CSF) samples from 60 children aged 0.5-18 years, including 43 children with a definitive diagnosis of PTC and a control group of 17 children. Levels of IL-4, IL-10, IL-17, CCL2, CCL7, CCL8, CCL13, BDNF, and IFN-γ were measured using ELISA kits. Levels of CCL2 were significantly higher in the PTC group compared to the control group (p < 0.05), with no other significant differences in the measured cytokines between the two groups. The groups did not differ significantly in clinical presentation, imaging, treatment, or ophthalmic findings. Our findings provide preliminary evidence that CCL2 may be involved in the pathogenesis of PTC and may serve a potential target for therapy in PTC.
Collapse
Affiliation(s)
- Jacob Genizi
- Pediatric Department, Bnai Zion Medical Center, Haifa 3104802, Israel
- Bruce Rappaport Faulty of Medicine, Technion, Haifa 3109601, Israel
| | - Lotan Berger
- Pediatric Department, Bnai Zion Medical Center, Haifa 3104802, Israel
| | - Muhammad Mahajnah
- Bruce Rappaport Faulty of Medicine, Technion, Haifa 3109601, Israel
- Pediatric Neurology Unit, Hillel Yaffe Medical Center, Hadera 3810000, Israel
| | - Yulia Shlonsky
- Microbiology Lab, Bnai Zion Medical Center, Haifa 3104802, Israel
| | - Orit Golan-Shany
- Microbiology Lab, Bnai Zion Medical Center, Haifa 3104802, Israel
| | - Azriel Romem
- Pediatric Department, Bnai Zion Medical Center, Haifa 3104802, Israel
| | - Ayelet Halevy
- Department of Pediatric Neurology, Schneider Children's Medical Center of Israel, Petah Tikva 4920235, Israel
| | - Keren Nathan
- Pediatric Department, Bnai Zion Medical Center, Haifa 3104802, Israel
| | - Rajech Sharkia
- Beit-Berl Academic College, Beit-Berl 4490500, Israel
- Unit of Human Biology and Genetics, Triangle Regional Research and Development Center, Kfar Qari' 3007500, Israel
| | - Abdelnaser Zalan
- Unit of Human Biology and Genetics, Triangle Regional Research and Development Center, Kfar Qari' 3007500, Israel
| | - Aharon Kessel
- Bruce Rappaport Faulty of Medicine, Technion, Haifa 3109601, Israel
- Division of Allergy and Clinical Immunology, Bnai Zion Medical Center, Haifa 3104802, Israel
| | - Rony Cohen
- Department of Pediatric Neurology, Schneider Children's Medical Center of Israel, Petah Tikva 4920235, Israel
- Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel
| |
Collapse
|
3
|
Grumach AS, Gadir N, Kessel A, Yegin A, Martinez-Saguer I, Bernstein JA. Current challenges and future opportunities in patient-focused management of hereditary angioedema: A narrative review. Clin Transl Allergy 2023; 13:e12243. [PMID: 37227422 DOI: 10.1002/clt2.12243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2022] [Revised: 03/15/2023] [Accepted: 04/04/2023] [Indexed: 05/26/2023] Open
Abstract
Patients with hereditary angioedema (HAE) experience a high burden of disease due to unpredictable, painful, disfiguring, and potentially life-threatening HAE attacks. Multiple HAE-specific medications for the on-demand treatment, short-term and long-term prophylaxis of HAE attacks have entered the market in recent years; however, the availability and access to these medications may vary between different countries. For this review, PubMed and EMBASE databases were searched for guidelines, consensus statements, and other publications on HAE management as well as publications on quality of life in patients with HAE. The current guidelines and recent literature on HAE management in specific countries are summarized with the aim to highlight the similarities and differences between guideline recommendations and the country-specific clinical practice. Improvement in quality of life, which is a key goal in HAE management, is also discussed and the country-specific trends are highlighted. Finally, the ways to achieve a more patient-centric approach to HAE management within the framework set by the clinical management guidelines are examined.
Collapse
Affiliation(s)
- Anete S Grumach
- Clinical Immunology, Faculdade de Medicina, Centro Universitario Faculdade de Medicina ABC (FMABC), Santo Andre, Brazil
| | - Noga Gadir
- Takeda Development Center Americas, Inc., Lexington, Massachusetts, USA
| | - Aharon Kessel
- Division of Allergy and Clinical Immunology, Bnai Zion Medical Centre, Technion Faculty of Medicine, Haifa, Israel
| | - Ashley Yegin
- Takeda Development Center Americas, Inc., Lexington, Massachusetts, USA
| | | | - Jonathan A Bernstein
- Division of Rheumatology, Allergy and Immunology, University of Cincinnati College of Medicine and Bernstein Clinical Research Center, Cincinnati, Ohio, USA
| |
Collapse
|
4
|
Zuberbier T, Abdul Latiff AH, Abuzakouk M, Aquilina S, Asero R, Baker D, Ballmer‐Weber B, Bangert C, Ben‐Shoshan M, Bernstein JA, Bindslev‐Jensen C, Brockow K, Brzoza Z, Chong Neto HJ, Church MK, Criado PR, Danilycheva IV, Dressler C, Ensina LF, Fonacier L, Gaskins M, Gáspár K, Gelincik A, Giménez‐Arnau A, Godse K, Gonçalo M, Grattan C, Grosber M, Hamelmann E, Hébert J, Hide M, Kaplan A, Kapp A, Kessel A, Kocatürk E, Kulthanan K, Larenas‐Linnemann D, Lauerma A, Leslie TA, Magerl M, Makris M, Meshkova RY, Metz M, Micallef D, Mortz CG, Nast A, Oude‐Elberink H, Pawankar R, Pigatto PD, Ratti Sisa H, Rojo Gutiérrez MI, Saini SS, Schmid‐Grendelmeier P, Sekerel BE, Siebenhaar F, Siiskonen H, Soria A, Staubach‐Renz P, Stingeni L, Sussman G, Szegedi A, Thomsen SF, Vadasz Z, Vestergaard C, Wedi B, Zhao Z, Maurer M. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy 2022; 77:734-766. [PMID: 34536239 DOI: 10.1111/all.15090] [Citation(s) in RCA: 319] [Impact Index Per Article: 159.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2021] [Revised: 08/31/2021] [Accepted: 09/06/2021] [Indexed: 02/07/2023]
Abstract
This update and revision of the international guideline for urticaria was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the Global Allergy and Asthma European Network (GA²LEN) and its Urticaria and Angioedema Centers of Reference and Excellence (UCAREs and ACAREs), the European Dermatology Forum (EDF; EuroGuiDerm), and the Asia Pacific Association of Allergy, Asthma and Clinical Immunology with the participation of 64 delegates of 50 national and international societies and from 31 countries. The consensus conference was held on 3 December 2020. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). Urticaria is a frequent, mast cell-driven disease that presents with wheals, angioedema, or both. The lifetime prevalence for acute urticaria is approximately 20%. Chronic spontaneous or inducible urticaria is disabling, impairs quality of life, and affects performance at work and school. This updated version of the international guideline for urticaria covers the definition and classification of urticaria and outlines expert-guided and evidence-based diagnostic and therapeutic approaches for the different subtypes of urticaria.
Collapse
Affiliation(s)
- Torsten Zuberbier
- Comprehensive Allergy Centre Charité Charité – Universitätsmedizin BerlinCorporate Member of Freie Universität BerlinHumboldt‐Universität zu Berlin, and Berlin Institute of Health Berlin Germany
| | | | - Mohamed Abuzakouk
- Department of Allergy and Immunology Respiratory InstituteCleveland Clinic Abu Dhabi Abu Dhabi United Arab Emirates
| | - Susan Aquilina
- Department of Dermatology Mater Dei Hospital Msida Malta
| | - Riccardo Asero
- Ambulatorio di Allergologia Clinica San Carlo Paderno Dugnano (MI) Italy
| | - Diane Baker
- Baker Allergy Asthma and Dermatology Portland Oregon USA
| | - Barbara Ballmer‐Weber
- Clinic for Dermatology and Allergology Kantonsspital St. Gallen St. Gallen Switzerland
- Department of Dermatology University Hospital Zurich Zurich Switzerland
| | - Christine Bangert
- Department of Dermatology Medical University of Vienna Vienna Austria
| | - Moshe Ben‐Shoshan
- Division of Allergy, Immunology and Dermatology Department of Pediatrics Montreal Children’s Hospital McGill University Montreal Quebec Canada
| | | | - Carsten Bindslev‐Jensen
- Department of Dermatology and Allergy Centre Odense University Hospital and University of Southern Denmark Odense Denmark
| | - Knut Brockow
- Department of Dermatology and Allergy Biederstein Faculty of Medicine Technical University Munich Munich Germany
| | - Zenon Brzoza
- Department of Internal Diseases with Division of Allergology University of Opole Opole Poland
| | - Herberto Jose Chong Neto
- Division of Allergy and Immunology Department of Pediatrics Federal University of Paraná Curitiba Brazil
| | - Martin K. Church
- Comprehensive Allergy Centre Charité Charité – Universitätsmedizin BerlinCorporate Member of Freie Universität BerlinHumboldt‐Universität zu Berlin, and Berlin Institute of Health Berlin Germany
- University of Southampton Southampton UK
| | - Paulo R. Criado
- Sociedade Brasileira de Dermatologia (SBD) Centro Universitário FMABCAlergoskin (UCARE) Santo André Brazil
| | - Inna V. Danilycheva
- Department of Allergology and Immunotherapy National Research Center‐Institute of Immunology Federal Medical‐Biological Agency of Russia Moscow Russia
| | - Corinna Dressler
- Division of Evidence‐Based Medicine Department of Dermatology, Venereology and Allergy Charité – Universitätsmedizin BerlinCorporate Member of Freie Universität BerlinHumboldt‐Universität zu Berlin, and Berlin Institute of Health Berlin Germany
| | - Luis Felipe Ensina
- Division of Allergy Clinical Immunology and Rheumatology Department of Pediatrics Federal University of São Paulo São Paulo Brazil
| | - Luz Fonacier
- New York University Long Island School of Medicine New York New York USA
| | - Matthew Gaskins
- Division of Evidence‐Based Medicine Department of Dermatology, Venereology and Allergy Charité – Universitätsmedizin BerlinCorporate Member of Freie Universität BerlinHumboldt‐Universität zu Berlin, and Berlin Institute of Health Berlin Germany
| | - Krisztian Gáspár
- Division of Dermatological Allergology Department of Dermatology Faculty of Medicine University of Debrecen Debrecen Hungary
| | - Aslı Gelincik
- Division of Immunology and Allergic Diseases Department of Internal Medicine Istanbul Faculty of Medicine Istanbul University Istanbul Turkey
| | - Ana Giménez‐Arnau
- Department of Dermatology, Hospital del Mar Institut Mar d’Investigacions Mèdiques Universitat Autònoma y Universitat Pompeu Fabra Barcelona Spain
| | - Kiran Godse
- Department of Dermatology D Y Patil University School of MedicineNavi Mumbai India
| | - Margarida Gonçalo
- Department of Dermatology Coimbra University Hospital and Faculty of Medicine University of Coimbra Coimbra Portugal
| | - Clive Grattan
- Guy’s HospitalSt John’s Institute of Dermatology London UK
| | - Martine Grosber
- Department of Dermatology Universitair Ziekenhuis Brussel (UZ Brussel)Vrije Universiteit Brussel (VUB) Brussels Belgium
| | - Eckard Hamelmann
- Department of Pediatrics Children’s Center Bethel University Hospital OWLUniversity Bielefeld Bielefeld Germany
| | - Jacques Hébert
- Service d'allergie Centre Hospitalier Université Laval/Centre Hospitalier Universitaire de Québec Québec Quebec Canada
| | - Michihiro Hide
- Department of Dermatology Hiroshima University Hiroshima Japan
- Department of Dermatology Hiroshima Citizens Hospital Hiroshima Japan
| | - Allen Kaplan
- Department of Medicine Division of Pulmonary and Critical Care Medicine, Allergy and Clinical Immunology Medical University of South Carolina Charleston South Carolina USA
| | - Alexander Kapp
- Department of Dermatology & Allergy Hannover Medical School (MHH) Hannover Germany
| | - Aharon Kessel
- Division of Allergy and Clinical Immunology Bnai Zion Medical Center and the Bruce and Ruth Rappaport Faculty of Medicine Technion Haifa Israel
| | - Emek Kocatürk
- Department of Dermatology Koç University School of Medicine Istanbul Turkey
| | - Kanokvalai Kulthanan
- Department of Dermatology Faculty of Medicine Siriraj Hospital Mahidol University Bangkok Thailand
| | | | - Antti Lauerma
- Department of Dermatology, Allergology and Venereology Inflammation Centre University of Helsinki and Helsinki University Hospital Helsinki Finland
| | | | - Markus Magerl
- Comprehensive Allergy Centre Charité Charité – Universitätsmedizin BerlinCorporate Member of Freie Universität BerlinHumboldt‐Universität zu Berlin, and Berlin Institute of Health Berlin Germany
- Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology Berlin Germany
| | - Michael Makris
- Allergy Unit 2nd Department of Dermatology and Venereology National and Kapodistrian University of AthensUniversity General Hospital "Attikon" Athens Greece
| | - Raisa Y. Meshkova
- Department of Clinical Immunology and Allergology Smolensk State Medical University Smolensk Russia
| | - Martin Metz
- Comprehensive Allergy Centre Charité Charité – Universitätsmedizin BerlinCorporate Member of Freie Universität BerlinHumboldt‐Universität zu Berlin, and Berlin Institute of Health Berlin Germany
- Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology Berlin Germany
| | | | - Charlotte G. Mortz
- Department of Dermatology and Allergy Centre Odense Research Center for Anaphylaxis (ORCA) Odense University Hospital and University of Southern Denmark Odense Denmark
| | - Alexander Nast
- Division of Evidence‐Based Medicine Department of Dermatology, Venereology and Allergy Charité – Universitätsmedizin BerlinCorporate Member of Freie Universität BerlinHumboldt‐Universität zu Berlin, and Berlin Institute of Health Berlin Germany
| | | | - Ruby Pawankar
- Department of Pediatrics Nippon Medical School Tokyo Japan
| | - Paolo D. Pigatto
- Department of Biomedical Surgical and Dental Sciences University of Milan Milan Italy
| | - Hector Ratti Sisa
- Primera Cátedra de Clínica Médica Hospital de Clínicas de la Facultad de Ciencias Médicas‐Universidad Nacional de Asunción Asunción Paraguay
| | | | | | | | - Bulent E. Sekerel
- Division of Pediatric Allergy and Asthma Hacettepe University Faculty of Medicine Ankara Turkey
| | - Frank Siebenhaar
- Comprehensive Allergy Centre Charité Charité – Universitätsmedizin BerlinCorporate Member of Freie Universität BerlinHumboldt‐Universität zu Berlin, and Berlin Institute of Health Berlin Germany
- Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology Berlin Germany
| | - Hanna Siiskonen
- Department of Pathology Diagnostic Imaging Centre Kuopio University Hospital Kuopio Finland
| | - Angele Soria
- Department of Dermatology and Allergology Tenon Hospital APHP Sorbonne University and Cimi‐Paris Inserm 1135 Paris France
| | | | - Luca Stingeni
- Dermatology Section Department of Medicine University of Perugia Perugia Italy
| | - Gordon Sussman
- Division of Allergy and Clinical Immunology St. Michael's Hospital and University of Toronto Toronto Canada
| | - Andrea Szegedi
- Division of Dermatological Allergology Department of Dermatology Faculty of Medicine University of Debrecen Debrecen Hungary
| | - Simon Francis Thomsen
- Department of Dermatology Bispebjerg Hospital University of Copenhagen Copenhagen Denmark
| | - Zahava Vadasz
- Proteomic and Clinical Flow Cytometry Unit Bnai Zion Medical Center Rappaport Faculty of Medicine Technion Haifa Israel
| | | | - Bettina Wedi
- Department of Dermatology and Allergy Comprehensive Allergy Center Hannover Medical School Hannover Germany
| | - Zuotao Zhao
- Department of Dermatology and Venereology Peking University First Hospital Beijing China
| | - Marcus Maurer
- Comprehensive Allergy Centre Charité Charité – Universitätsmedizin BerlinCorporate Member of Freie Universität BerlinHumboldt‐Universität zu Berlin, and Berlin Institute of Health Berlin Germany
- Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology Berlin Germany
| |
Collapse
|
5
|
Sagiv M, Adawi M, Awisat A, Shouval A, Peri R, Sabbah F, Rosner I, Kessel A, Slobodin G. The association between elevated serum interleukin-22 and the clinical diagnosis of axial spondyloarthritis: A retrospective study. Int J Rheum Dis 2022; 25:56-60. [PMID: 34806316 DOI: 10.1111/1756-185x.14246] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2021] [Revised: 10/30/2021] [Accepted: 11/07/2021] [Indexed: 12/20/2022]
Abstract
OBJECTIVE There is an unmet need for a reliable biomarker for the differentiation of axial spondyloarthritis (AxSpA) from its mimickers. Serum levels of interleukin-22 (IL-22) have previously been found to be significantly elevated in patients with AxSpA compared with healthy individuals or persons with osteoarthritis. METHODS Consecutive patients with established or suspected AxSpA were enrolled. The clinical data, as well as results of laboratory and imaging studies, were acquired from patients' charts. The final diagnosis of definite or probable SpA, or an alternative diagnosis, was determined, and the serum levels of IL-22 were examined by enzyme-linked immunosorbent immunoassay. RESULTS Interleukin-22 levels were significantly higher in patients with definite AxSpA (29 patients) compared with patients with alternative diagnoses (14 patients) and healthy volunteers (16 individuals; P < 0.001 for both comparisons). The sensitivity and specificity of the serum IL-22 for the AxSpA diagnosis were 0.68 (95% CI 0.49-0.84) and 0.86 (95% CI 0.68-0.95), respectively, for the cut-off value of 5 pg/mL. In patients with AxSpA, serum IL-22 levels did not correlate with modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Ankylosing Spondylitis Disease Activity Score (ASDAS), or serum C-reactive protein. CONCLUSION Serum IL-22 levels are elevated in patients with the clinical diagnosis of AxSpA and can potentially serve as an independent biomarker for the differentiation of AxSpA from its non-inflammatory mimickers.
Collapse
Affiliation(s)
- Michal Sagiv
- Faculty of Medicine, Bar Ilan University, Ramat Gan, Israel
| | - Mohammad Adawi
- Faculty of Medicine, Bar Ilan University, Ramat Gan, Israel
- Rheumatology Unit, Puria Medical Center, Tiberias, Israel
| | - Abid Awisat
- Rheumatology Unit, Bnai Zion Medical Center, Haifa, Israel
| | - Aniela Shouval
- Rheumatology Unit, Bnai Zion Medical Center, Haifa, Israel
| | - Regina Peri
- Clinical Immunology and Allergy Division, Bnai Zion Medical Center, Haifa, Israel
| | - Firas Sabbah
- Rheumatology Unit, Puria Medical Center, Tiberias, Israel
| | - Itzhak Rosner
- Rheumatology Unit, Bnai Zion Medical Center, Haifa, Israel
- Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
| | - Aharon Kessel
- Clinical Immunology and Allergy Division, Bnai Zion Medical Center, Haifa, Israel
- Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
| | - Gleb Slobodin
- Rheumatology Unit, Bnai Zion Medical Center, Haifa, Israel
- Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
| |
Collapse
|
6
|
Sagiv M, Adawi M, Awisat A, Shouval A, Peri R, Sabbah F, Rosner I, Kessel A, Slobodin G. Response to a letter by M. Slouma et al. Int J Rheum Dis 2021; 25:238. [PMID: 34970855 DOI: 10.1111/1756-185x.14274] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2021] [Accepted: 12/22/2021] [Indexed: 11/29/2022]
Affiliation(s)
- Michal Sagiv
- Faculty of Medicine, Bar Ilan University, Ramat Gan, Israel
| | - Mohammad Adawi
- Faculty of Medicine, Bar Ilan University, Ramat Gan, Israel.,Rheumatology Unit, Puria Medical Center, Tiberias, Israel
| | - Abid Awisat
- Rheumatology Unit, Bnai Zion Medical Center, Haifa, Israel
| | - Aniela Shouval
- Rheumatology Unit, Bnai Zion Medical Center, Haifa, Israel
| | - Regina Peri
- Clinical Immunology and Allergy Division, Bnai Zion Medical Center, Haifa, Israel
| | - Firas Sabbah
- Rheumatology Unit, Puria Medical Center, Tiberias, Israel
| | - Itzhak Rosner
- Rheumatology Unit, Bnai Zion Medical Center, Haifa, Israel.,Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
| | - Aharon Kessel
- Clinical Immunology and Allergy Division, Bnai Zion Medical Center, Haifa, Israel.,Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
| | - Gleb Slobodin
- Rheumatology Unit, Bnai Zion Medical Center, Haifa, Israel.,Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
| |
Collapse
|
7
|
Fireman Klein E, Klein I, Ephrat O, Dekel Y, Kessel A, Adir Y. Trajectory of inhaled cadmium ultrafine particles in smokers. BMJ Open Respir Res 2021; 8:8/1/e001000. [PMID: 34845007 PMCID: PMC8633997 DOI: 10.1136/bmjresp-2021-001000] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2021] [Accepted: 11/09/2021] [Indexed: 11/09/2022] Open
Abstract
Introduction Tobacco smoking is a significant source of cadmium exposure among smokers. Most of inhaled heavy metals, including cadmium, are attached to ultrafine particles (UFPs) surface. A low inhaled UFP content in exhaled breath condensate reflects a high inflammatory status of airways. Increased respiratory epithelial permeability and translocation to the circulation is the proposed mechanism. UFP recovered from smokers’ airways have high levels of cadmium compared with the airways of non-smokers. Methods Urine was collected from 22 smokers subjects and 43 non-smokers. Samples were analysed for UFP and cadmium content. UFP were measured in urine samples by means of the NanoSight LM20 system (NanoSight, UK). A Niton XL3 X-ray fluorescence spectrometer analyzer (Thermo Fischer Scientific, Germany) quantified heavy metal contents in the urine samples. Results Smokers had elevated UFP and cadmium content in urine compared with non-smokers (4.6 E8/mL and 20.6 ppm vs 3.4 E8/mL and 18.5 ppm, p=0.05 and p=0.05, respectively). Smokers had elevated levels of lead and rubidium compared with non-smokers (8.9 ppm and 27 ppm vs 7.8 ppm and 2 ppm, p=0.05 and p=0.04, respectively) Discussion We suggest that the trajectory of cadmium-related UFP in smokers begins by its inhalation into the airways. The UFPs induce inflammation and oxidative stress in the small airways, are subsequently translocated from the interstitium to the circulation and are finally detected and secreted in urine
Collapse
Affiliation(s)
- Einat Fireman Klein
- B. Rappaport Faculty of Medicine, Technion- Israel Institute of Technology, Haifa, Israel .,Pulmonary Division, Lady Davis Carmel Medical Center, Haifa, Israel
| | - Ilan Klein
- B. Rappaport Faculty of Medicine, Technion- Israel Institute of Technology, Haifa, Israel.,Department of Urology, Lady Davis Carmel Medical Center, Haifa, Israel
| | - Omer Ephrat
- B. Rappaport Faculty of Medicine, Technion- Israel Institute of Technology, Haifa, Israel.,Department of Urology, Lady Davis Carmel Medical Center, Haifa, Israel
| | - Yoram Dekel
- B. Rappaport Faculty of Medicine, Technion- Israel Institute of Technology, Haifa, Israel.,Department of Urology, Lady Davis Carmel Medical Center, Haifa, Israel
| | - Aharon Kessel
- B. Rappaport Faculty of Medicine, Technion- Israel Institute of Technology, Haifa, Israel.,Division of Clinical Immunology and Allergy, Bnai Zion Medical center, Haifa, Israel
| | - Yochai Adir
- B. Rappaport Faculty of Medicine, Technion- Israel Institute of Technology, Haifa, Israel.,Pulmonary Division, Lady Davis Carmel Medical Center, Haifa, Israel
| |
Collapse
|
8
|
Iancovici L, Khateeb D, Harel O, Peri R, Slobodin G, Hazan Y, Melamed D, Kessel A, Bar-On Y. Rheumatoid arthritis patients treated with Janus kinase inhibitors show reduced humoral immune responses following BNT162b2 vaccination. Rheumatology (Oxford) 2021; 61:3439-3447. [PMID: 34849628 PMCID: PMC8767876 DOI: 10.1093/rheumatology/keab879] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2021] [Revised: 11/17/2021] [Indexed: 12/13/2022] Open
Abstract
Objectives The mRNA-based COVID-19 vaccines are now employed globally and have shown high efficacy in preventing SARS-CoV-2 infection. However, less is known about the vaccine efficacy in immune-suppressed individuals. This study sought to explore whether humoral immunity to the COVID-19 vaccine BNT162b2 is altered in RA patients treated with Janus kinase inhibitors by analysing their antibodies titre, neutralization activity and B cell responses. Methods We collected plasma samples from 12 RA patients who were treated with Janus kinase inhibitors and received two doses of the BNT162b2 vaccine, as well as 26 healthy individuals who were vaccinated with the same vaccine. We analysed the quantity of the anti-spike IgG and IgA antibodies that were elicited following the BNT162b2 vaccination, the plasma neutralization capacity and the responsiveness of the B-lymphocytes. We used ELISA to quantify the antibody titres, and a plasma neutralization assay was used to determine the virus neutralization capacity. Alteration in expression of the genes that are associated with B cell activation and the germinal centre response were analysed by quantitative PCR. Results Reduced levels of anti-spike IgG antibodies and neutralization capacity were seen in the RA patients who were treated with JAK inhibitors in comparison with healthy individuals. Furthermore, B cell responsiveness to the SARS-CoV-2 spike protein was reduced in the RA patients. Conclusion RA patients who are treated with JAK inhibitors show a suppressed humoral response following BNT162b2 vaccination, as revealed by the quantity and quality of the anti-spike antibodies.
Collapse
Affiliation(s)
- Liat Iancovici
- Department of Immunology, Technion-Israel Institute of Technology, Haifa, 31096, Israel
| | - Dina Khateeb
- Department of Immunology, Technion-Israel Institute of Technology, Haifa, 31096, Israel
| | - Ofer Harel
- Department of Immunology, Technion-Israel Institute of Technology, Haifa, 31096, Israel
| | - Regina Peri
- Division of Allergy and Clinical Immunology, Bnai Zion Medical Center, Haifa, Rappaport Faculty of Medicine, Technion, Haifa, Israel
| | - Gleb Slobodin
- Rheumatology Unit, Bnai Zion Medical Center, affiliated with Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
| | - Yoav Hazan
- Technion-Israel Institute of Technology, Haifa, 31096, Israel
| | - Doron Melamed
- Department of Immunology, Technion-Israel Institute of Technology, Haifa, 31096, Israel
| | - Aharon Kessel
- Division of Allergy and Clinical Immunology, Bnai Zion Medical Center, Haifa, Rappaport Faculty of Medicine, Technion, Haifa, Israel
| | - Yotam Bar-On
- Department of Immunology, Technion-Israel Institute of Technology, Haifa, 31096, Israel
| |
Collapse
|
9
|
Kessel A, Bamberger E, Nachshon L, Rosman Y, Confino‐Cohen R, Elizur A. Safe administration of the Pfizer-BioNtTech COVID-19 vaccine following an immediate reaction to the first dose. Allergy 2021; 76:3538-3540. [PMID: 34370884 PMCID: PMC8441877 DOI: 10.1111/all.15038] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2021] [Accepted: 08/02/2021] [Indexed: 12/26/2022]
Affiliation(s)
- Aharon Kessel
- Division of Allergy & Clinical Immunology Bnai Zion Medical Center, Haifa Rappaport Faculty of Medicine Technion Haifa Israel
| | - Ellen Bamberger
- Division of Allergy & Clinical Immunology Bnai Zion Medical Center, Haifa Rappaport Faculty of Medicine Technion Haifa Israel
| | - Liat Nachshon
- Institute of Allergy, Immunology and Pediatric Pulmonology Yitzhak Shamir Medical Center Zerifin Israel
- Sackler School of Medicine Tel Aviv University Tel‐Aviv Israel
| | - Yossi Rosman
- Sackler School of Medicine Tel Aviv University Tel‐Aviv Israel
- Allergy and Clinical Immunology Unit Meir Medical Center Kfar Saba Israel
| | - Ronit Confino‐Cohen
- Sackler School of Medicine Tel Aviv University Tel‐Aviv Israel
- Allergy and Clinical Immunology Unit Meir Medical Center Kfar Saba Israel
| | - Arnon Elizur
- Institute of Allergy, Immunology and Pediatric Pulmonology Yitzhak Shamir Medical Center Zerifin Israel
- Sackler School of Medicine Tel Aviv University Tel‐Aviv Israel
| |
Collapse
|
10
|
Musallam N, Dalal I, Almog M, Epov L, Romem A, Bamberger E, Mandelberg A, Kessel A. Food allergic reactions during the Covid-19 pandemic lockdown in Israeli children. Pediatr Allergy Immunol 2021; 32:1580-1584. [PMID: 33978968 PMCID: PMC8236997 DOI: 10.1111/pai.13540] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/04/2021] [Revised: 03/30/2021] [Accepted: 05/07/2021] [Indexed: 01/17/2023]
Affiliation(s)
- Nadira Musallam
- Division of Allergy & Clinical Immunology, Bnai Zion Medical Center, Haifa, Israel.,Technion, Rappaport Faculty of Medicine, Haifa, Israel
| | - Ilan Dalal
- Department of Pediatrics, E. Wolfson Medical Center, Holon, Israel.,Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Meital Almog
- Division of Allergy & Clinical Immunology, Bnai Zion Medical Center, Haifa, Israel.,Technion, Rappaport Faculty of Medicine, Haifa, Israel
| | - Larisa Epov
- Division of Allergy & Clinical Immunology, Bnai Zion Medical Center, Haifa, Israel.,Technion, Rappaport Faculty of Medicine, Haifa, Israel
| | - Azriel Romem
- Technion, Rappaport Faculty of Medicine, The Department of Pediatrics, Bnai Zion Medical Center, Haifa, Israel
| | - Ellen Bamberger
- Technion, Rappaport Faculty of Medicine, The Department of Pediatrics, Bnai Zion Medical Center, Haifa, Israel
| | - Avigdor Mandelberg
- Department of Pediatrics, E. Wolfson Medical Center, Holon, Israel.,Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Aharon Kessel
- Division of Allergy & Clinical Immunology, Bnai Zion Medical Center, Haifa, Israel.,Technion, Rappaport Faculty of Medicine, Haifa, Israel
| |
Collapse
|
11
|
Spergel JM, Blaiss MS, Lio P, Kessel A, Cantrell WC, Takiya L, Werth JL, O'Connell MA, Zang C, Cork MJ. Efficacy and safety of crisaborole in patients with mild-to-moderate atopic dermatitis and other atopic comorbidities. Allergy Asthma Proc 2021; 42:425-431. [PMID: 34474712 DOI: 10.2500/aap.2021.42.210064] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Background: Crisaborole is a nonsteroidal anti-inflammatory phosphodiesterase 4 inhibitor that is approved for the treatment of patients with mild-to-moderate atopic dermatitis (AD); however, the efficacy and safety of crisaborole in patients with AD and other atopic comorbidities have not been investigated. Objective: This post hoc pooled analysis of the pivotal phase III studies (CrisADe CORE 1 and CORE 2) assessed the efficacy and safety of crisaborole versus vehicle in patients aged ≥ 2 years with mild-to-moderate AD and other atopic comorbidities. Methods: Patients with mild-to-moderate AD and a medical history of asthma, allergic rhinitis, or food allergies were identified. Efficacy assessments included the proportion of patients who achieved Investigator's Static Global Assessment (ISGA) success at day 29, ISGA clear or almost clear at day 29, and improvement in the Severity of Pruritus Scale score at week 4. Safety was assessed via treatment-emergent adverse events (TEAEs). Results: This analysis included 1522 patients (crisaborole, 1016; vehicle, 506); 26.2, 15.9, and 16.5% had a medical history of asthma, allergic rhinitis, and food allergies, respectively. The mean age was 12.2 years. A significantly greater proportion of patients treated with crisaborole achieved ISGA success at day 29 compared with patients treated with vehicle for most subgroups analyzed. Furthermore, a significantly greater proportion of patients treated with crisaborole achieved ISGA clear or almost clear at day 29 across all subgroups and demonstrated improvement in the Severity of Pruritus Scale score at week 4 versus patients treated with vehicle in most of the subgroups. Overall, most TEAEs were mild or moderate in severity; the most common treatment-related TEAE in patients with atopic comorbidities was application-site pain (crisaborole, 5.1%; vehicle, 1.7%). Conclusion: Crisaborole was efficacious and well tolerated in patients with mild-to-moderate AD and other atopic comorbidities, which suggested that crisaborole should be considered for the management of AD in this population. Clinical Trials NCT02118766 (CrisADe CORE 1) and NCT02118792 (CrisADe CORE 2), <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</ext-link>.
Collapse
Affiliation(s)
- Jonathan M. Spergel
- From the Division of Allergy and Immunology, Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine at University of Pennsylvania, Philadelphia, Pennsylvania
| | - Michael S. Blaiss
- Department of Pediatrics, Medical College of Georgia at Augusta University, Augusta, Georgia
| | - Peter Lio
- Department of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois
| | - Aharon Kessel
- Division of Allergy and Clinical Immunology, Bnai Zion Medical Center, Haifa, Israel
| | | | - Liza Takiya
- Medical Affairs, Pfizer Inc., Collegeville, Pennsylvania; and
| | - John L. Werth
- Medical Affairs, Pfizer Inc., Collegeville, Pennsylvania; and
| | | | - Chuanbo Zang
- Medical Affairs, Pfizer Inc., Collegeville, Pennsylvania; and
| | - Michael J. Cork
- Department of Infection, Immunity, and Cardiovascular Disease, Sheffield Dermatology Research, University of Sheffield, Sheffield Children's Hospital, Sheffield, United Kingdom
| |
Collapse
|
12
|
Lio PA, Spergel JM, Cork MJ, Blaiss MS, Kessel A, Cantrell WC, Werth JL, O’Connell MA, Zang C, Takiya L. 26304 Efficacy and safety of crisaborole in patients with mild-to-moderate atopic dermatitis with and without comorbid allergies or asthma. J Am Acad Dermatol 2021. [DOI: 10.1016/j.jaad.2021.06.406] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
13
|
Farkas H, Reshef A, Caballero T, Ortega López MC, Kessel A, Vardi M, Hao J, Aberer W. Continued icatibant use across recurrent attacks in adolescents with hereditary angioedema. Pediatr Allergy Immunol 2021; 32:1392-1396. [PMID: 33851451 PMCID: PMC8453719 DOI: 10.1111/pai.13519] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/28/2020] [Revised: 03/19/2021] [Accepted: 04/07/2021] [Indexed: 12/03/2022]
Affiliation(s)
- Henriette Farkas
- Department of Internal Medicine and Haematology, Hungarian Angioedema Center of Reference and Excellence, Semmelweis University, Budapest, Hungary
| | - Avner Reshef
- Allergy, Immunology, and Angioedema Center, Barzilai University Medical Center, Ashkelon, Israel
| | - Teresa Caballero
- Allergy Department, Hospital La Paz Institute for Health Research (IdiPAZ), Biomedical Research Network on Rare Diseases (CIBERER, U754), Madrid, Spain
| | - María C Ortega López
- Hospital Universitario Infantil de San José and Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia
| | - Aharon Kessel
- Bnai Zion Medical Center, Technion-Israel Institute of Technology, Haifa, Israel
| | - Moshe Vardi
- Takeda Pharmaceutical Company Limited, Lexington, MA, USA
| | - James Hao
- Takeda Pharmaceutical Company Limited, Lexington, MA, USA
| | - Werner Aberer
- Department of Dermatology, Medical University of Graz, Graz, Austria
| |
Collapse
|
14
|
Engel-Yeger B, Maurer M, Hawro T, Zubedat S, Avital A, Kessel A. Exaggerated neurophysiological responses to stressor in patients with chronic spontaneous urticaria. Clin Exp Allergy 2021; 51:936-938. [PMID: 33619775 DOI: 10.1111/cea.13854] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2020] [Revised: 01/23/2021] [Accepted: 02/06/2021] [Indexed: 01/19/2023]
Affiliation(s)
- Batya Engel-Yeger
- Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany.,Occupational Therapy Department, Faculty of Social Welfare and Health Sciences, University of Haifa, Haifa, Israel
| | - Marcus Maurer
- Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Tomasz Hawro
- Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Salman Zubedat
- Behavioral Neuroscience Lab, Department of Neuroscience, The Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel
| | - Avi Avital
- Behavioral Neuroscience Lab, Department of Neuroscience, The Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel
| | - Aharon Kessel
- Division of Allergy and Clinical Immunology, Technion Faculty of Medicine, Bnai Zion Medical Center, Haifa, Israel
| |
Collapse
|
15
|
Spergel J, Blaiss M, Lio P, Kessel A, Takiya L, Werth J, O'Connell M, Zang C, Cork M. Efficacy and Safety of Crisaborole in Patients With Mild-to-Moderate Atopic Dermatitis With Comorbid Allergic Rhinitis or Asthma. J Allergy Clin Immunol 2021. [DOI: 10.1016/j.jaci.2020.12.141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
16
|
Spergel J, Blaiss M, Lio P, Kessel A, Takiya L, Werth J, O'Connell M, Zang C, Cork M. P500 EFFICACY OF CRISABOROLE IN PATIENTS WITH MILD-TO-MODERATE ATOPIC DERMATITIS WITH AND WITHOUT COMORBID ALLERGIC RHINITIS. Ann Allergy Asthma Immunol 2020. [DOI: 10.1016/j.anai.2020.08.158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
17
|
Fireman Klein E, Adir Y, Fireman E, Kessel A. Cigarette-related cadmium and environmental pollution exposure are reflected in airway ultrafine particle content. ERJ Open Res 2020; 6:00361-2019. [PMID: 32963996 PMCID: PMC7487350 DOI: 10.1183/23120541.00361-2019] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2020] [Accepted: 06/15/2020] [Indexed: 11/05/2022] Open
Abstract
Introduction Particulate matter (PM) and cigarette-related cadmium exposure increases inflammation and smokers' susceptibility to developing lung diseases. The majority of inhaled metals are attached to the surface of ultrafine particles (UFPs). A low inhaled UFP content in exhaled breath condensate (EBC) reflects a high inflammatory status of airways. Methods EBC was collected from 58 COPD patients and 40 healthy smokers and nonsmokers. Participants underwent spirometry, diffusion capacity, EBC and blood sampling. Environmental pollution data were collected from monitoring stations. UFPs were measured in EBC and serum, and cadmium content was quantified. Results Subjects with low UFP concentrations in EBC (<0.18×108·mL-1) had been exposed to higher long-term PM2.5 levels versus subjects with high UFP concentrations in EBC (>0.18×108·mL-1) (21.9 µg·m-3 versus 17.4 µg·m-3, p≤0.001). Long-term PM2.5 exposure levels correlated negatively with UFP concentrations in EBC and positively with UFP concentrations in serum (r=-0.54, p≤0.001 and r=0.23, p=0.04, respectively). Healthy smokers had higher cadmium levels in EBC versus healthy nonsmokers and COPD patients (25.2 ppm versus 23.7 ppm and 23.3 ppm, p=0.02 and p=0.002, respectively). Subjects with low UFP concentrations in EBC also had low cadmium levels in EBC versus subjects with high UFP levels (22.8 ppm versus 24.2 ppm, p=0.004). Conclusions Low UFP concentration in EBC is an indicator of high-level PM exposure. High cadmium levels in EBC among smokers and the association between cadmium and UFP content in EBC among COPD patients indicate cadmium lung toxicity.
Collapse
Affiliation(s)
- Einat Fireman Klein
- Pulmonary Division, Carmel Medical Center, Haifa, Israel.,Dept of Internal Medicine B, Bnai-Zion Medical Center, Haifa, Israel.,Affiliated with the Rappaport Faculty of Medicine, Technion - Institute of Technology, Haifa, Israel
| | - Yochai Adir
- Pulmonary Division, Carmel Medical Center, Haifa, Israel.,Affiliated with the Rappaport Faculty of Medicine, Technion - Institute of Technology, Haifa, Israel
| | - Elizabeth Fireman
- The Institute of Pulmonary Diseases, National Laboratory Service for ILD, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.,Dept of Occupational and Environmental Medicine Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Aharon Kessel
- Division of Allergy and Clinical Immunology, Bnai-Zion Medical Center, Haifa, Israel.,Affiliated with the Rappaport Faculty of Medicine, Technion - Institute of Technology, Haifa, Israel
| |
Collapse
|
18
|
Maurer M, Aberer W, Agondi R, Al‐Ahmad M, Al‐Nesf MA, Ansotegui I, Arnaout R, Arruda LK, Asero R, Aygören‐Pürsün E, Banerji A, Bauer A, Ben‐Shoshan M, Berardi A, Bernstein JA, Betschel S, Bindslev‐Jensen C, Bizjak M, Boccon‐Gibod I, Bork K, Bouillet L, Boysen HB, Brodszki N, Broesby‐Olsen S, Busse P, Buttgereit T, Bygum A, Caballero T, Campos RA, Cancian M, Cherrez‐Ojeda I, Cohn DM, Costa C, Craig T, Criado PR, Criado RF, Csuka D, Dissemond J, Du‐Thanh A, Ensina LF, Ertaş R, Fabiani JE, Fantini C, Farkas H, Ferrucci SM, Figueras‐Nart I, Fili NL, Fomina D, Fukunaga A, Gelincik A, Giménez‐Arnau A, Godse K, Gompels M, Gonçalo M, Gotua M, Gower R, Grumach AS, Guidos‐Fogelbach G, Hide M, Ilina N, Inomata N, Jakob T, Josviack DO, Kang H, Kaplan A, Kasperska‐Zając A, Katelaris C, Kessel A, Kleinheinz A, Kocatürk E, Košnik M, Krasowska D, Kulthanan K, Kumaran MS, Larco Sousa JI, Longhurst HJ, Lumry W, MacGinnitie A, Magerl M, Makris MP, Malbrán A, Marsland A, Martinez‐Saguer I, Medina IV, Meshkova R, Metz M, Nasr I, Nicolay J, Nishigori C, Ohsawa I, Özyurt K, Papadopoulos NG, Parisi CAS, Peter JG, Pfützner W, Popov T, Prior N, Ramon GD, Reich A, Reshef A, Riedl MA, Ritchie B, Röckmann‐Helmbach H, Rudenko M, Salman A, Sanchez‐Borges M, Schmid‐Grendelmeier P, Serpa FS, Serra‐Baldrich E, Sheikh FR, Smith W, Soria A, Staubach P, Steiner UC, Stobiecki M, Sussman G, Tagka A, Thomsen SF, Treudler R, Valle S, Doorn M, Varga L, Vázquez DO, Wagner N, Wang L, Weber‐Chrysochoou C, Ye Y, Zalewska‐Janowska A, Zanichelli A, Zhao Z, Zhi Y, Zuberbier T, Zwiener RD, Castaldo A. Definition, aims, and implementation of GA 2 LEN/HAEi Angioedema Centers of Reference and Excellence. Allergy 2020; 75:2115-2123. [PMID: 32248571 DOI: 10.1111/all.14293] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2020] [Revised: 03/16/2020] [Accepted: 03/18/2020] [Indexed: 01/12/2023]
Affiliation(s)
- Marcus Maurer
- Department of Dermatology and Allergy Dermatological Allergology Allergie‐Centrum‐Charité Charité—Universitätsmedizin Berlin Berlin Germany
| | - Werner Aberer
- Department of Dermatology Medical University of Graz Graz Austria
| | | | - Mona Al‐Ahmad
- Microbiology Department Faculty of Medicine Kuwait University Safat Kuwait
| | - Maryam Ali Al‐Nesf
- Allergy and Immunology Section Department of Medicine Hamad General Hospital Doha Qatar
| | - Ignacio Ansotegui
- Department of Allergy and Immunology Hospital Quiron Bizkaia Bizkaia Spain
| | - Rand Arnaout
- King Faisal Specialist Hospital & Research Center Al Faisal University Riyadh Saudi Arabia
| | | | - Riccardo Asero
- Ambulatorio di Allergologia Clinica San Carlo Paderno Dugnano (MI) Italy
| | - Emel Aygören‐Pürsün
- Center for Children and Adolescents University Hospital Frankfurt Frankfurt Germany
| | - Aleena Banerji
- Division of Rheumatology, Allergy and Immunology Massachusetts General Hospital Boston MA USA
| | - Andrea Bauer
- Department of Dermatology University Allergy Center University Hospital Carl Gustav Carus Technical University Dresden Germany
| | - Moshe Ben‐Shoshan
- Division of Allergy, Immunology and Dermatology Department of Pediatrics McGill University Health Center Montreal QC Canada
| | - Alejandro Berardi
- Instituto de Asma Alergia y Enfermedades Respiratorias Corrientes Argentina
| | - Jonathan A. Bernstein
- Allergy Section Division of Immunology Department of Internal Medicine Partner Bernstein Allergy Group Partner Bernstein Clinical Research Center University of Cincinnati Cincinnati OH USA
| | - Stephen Betschel
- Division of Clinical Immunology and Allergy St. Michael’s Hospital University of Toronto Toronto ON Canada
| | | | - Mojca Bizjak
- Division of Allergy University Clinic of Respiratory and Allergic Diseases Golnik Golnik Slovenia
| | - Isabelle Boccon‐Gibod
- Clinical Immunology/Internal Medicine Department National Reference Center for Angioedema Grenoble University Hospital Grenoble France
| | - Konrad Bork
- Department of Dermatology Johannes Gutenberg University Mainz Mainz Germany
| | - Laurence Bouillet
- Clinical Immunology/Internal Medicine Department National Reference Center for Angioedema Grenoble University Hospital Grenoble France
| | | | | | - Sigurd Broesby‐Olsen
- Department of Dermatology and Allergy Center Odense University Hospital Odense Denmark
| | - Paula Busse
- Division of Clinical Immunology Icahn School at Mount Sinai New York NY USA
| | - Thomas Buttgereit
- Department of Dermatology and Allergy Dermatological Allergology Allergie‐Centrum‐Charité Charité—Universitätsmedizin Berlin Berlin Germany
| | - Anette Bygum
- HAE Centre Odense University Hospital Odense Denmark
| | - Teresa Caballero
- Allergy Department Hospital Universitario La Paz IdiPaz, CIBERER U754 Madrid Spain
| | - Régis A. Campos
- Universidade Federal da Bahia Salvador Brazil
- Serviço de Imunologia Hospital das Clínicas Professor Edgard Santos Salvador Brazil
| | - Mauro Cancian
- Department of Systems Medicine University Hospital of Padua Padua Italy
| | - Ivan Cherrez‐Ojeda
- School of Medicine Universidad de Especialidades Espíritu Santo Samborondón Ecuador
- RespiraLab, Research Guayaquil Ecuador
| | - Danny M. Cohn
- Department of Vascular Medicine Amsterdam UMC University of Amsterdam Amsterdam The Netherlands
| | - Célia Costa
- Immunoallergology Department Hospital de Santa Maria Centro Hospitalar Universitário de Lisboa Norte (CHLN) EPE Lisbon Portugal
| | - Timothy Craig
- Department of Medicine and Pediatrics Penn State University Hershey PA USA
| | - Paulo Ricardo Criado
- Faculdade de Medicina do ABC Santo André Brazil
- Alergoskin Alergia e Dermatologia SS ltda Santo André Brazil
- UCARE Center São Paulo Brazil
| | | | - Dorottya Csuka
- 3rd Department of Internal Medicine Hungarian Angioedema Reference Center Semmelweis University Budapest Hungary
| | - Joachim Dissemond
- Department of Dermatology, Venereology and Allergology University of Essen Essen Germany
| | - Aurélie Du‐Thanh
- Service de Dermatologie‐allergologie CHU Montpellier Montpellier Cedex 5 France
| | - Luis Felipe Ensina
- Division of Allergy, Clinical Immunology and Rheumatology Department of Pediatrics Federal University of São Paulo São Paulo Brazil
| | - Ragıp Ertaş
- Department of Dermatology Kayseri City Education and Research Hospital Kayseri Turkey
| | | | - Claudio Fantini
- Servicio de Alergia e Inmunología—Hospital Alende y Clínica Colón Mar del Plata Argentina
| | - Henriette Farkas
- 3rd Department of Internal Medicine Hungarian Angioedema Reference Center Semmelweis University Budapest Hungary
| | - Silvia Mariel Ferrucci
- Ambulatorio di Dermatologia Allergologica e Professionale Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico Milano (MI) Italy
| | - Ignasi Figueras‐Nart
- The Dermatology Department of the Hospital de Bellvitge Universitat de Barcelona Barcelona Spain
| | - Natalia L. Fili
- Unidad Alergia e Inmunología Clínica Hospital Público Materno Infantil Salta Argentina
| | - Daria Fomina
- Center of Allergy and Immunology City Clinical Hospital No. 52 Moscow Ministry of Healthcare Moscow Russian Federation
- Department of Allergology and Clinical Immunology I.M. Sechenov First Moscow State Medical University Moscow Russian Federation
| | - Atsushi Fukunaga
- Division of Dermatology Graduate School of Medicine Kobe University Kobe Japan
| | - Asli Gelincik
- Division of Immunology and Allergic Diseases Department of Internal Medicine Istanbul Faculty of Medicine Istanbul University Istanbul Turkey
| | - Ana Giménez‐Arnau
- Department of Dermatology Hospital del Mar IMIM Universitat Autònoma Barcelona Spain
| | - Kiran Godse
- Department of Dermatology D Y. Patil University School of Medicine Mumbai India
| | - Mark Gompels
- Department of Immunology North Bristol NHS Trust Southmead Hospital Bristol UK
| | - Margarida Gonçalo
- Clinica de Dermatologia Centro Hospitalar Universitário Coimbra Coimbra Portugal
| | - Maia Gotua
- Center of Allergy and Immunology Tbilsi Georgia
| | | | - Anete S. Grumach
- Clinical Immunology Medical School University Center Health ABC Santo Andre Brazil
| | | | - Michihiro Hide
- Department of Dermatology Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima Japan
| | | | - Naoko Inomata
- Department of Environmental Immuno‐Dermatology Yokohama City University Graduate School of Medicine Yokohama Japan
| | - Thilo Jakob
- Department of Dermatology and Allergy University Medical Center Giessen (UKGM) Justus‐Liebig‐University Giessen Giessen Germany
| | | | - Hye‐Ryun Kang
- Institute of Allergy and Clinical Immunology Seoul National University Medical Research Center Seoul Korea
| | - Allen Kaplan
- Medical University of South Carolina Charleston SC USA
| | | | - Constance Katelaris
- Immunology & Allergy Unit Department of Medicine Campbelltown Hospital Campbelltown NSW Australia
| | - Aharon Kessel
- Division of Allergy & Clinical Immunology Rappaport Faculty of Medicine Bnai Zion Medical Center Technion Haifa Israel
| | | | - Emek Kocatürk
- Department of Dermatology School of Medicine Koç University Koc Turkey
| | - Mitja Košnik
- Division of Allergy University Clinic of Respiratory and Allergic Diseases Golnik Golnik Slovenia
| | - Dorota Krasowska
- Department of Dermatology, Venerology and Pediatric Dermatology Medical University of Lublin Lublin Poland
| | - Kanokvalai Kulthanan
- Department of Dermatology Faculty of Medicine Siriraj Hospital Mahidol University Bangkok Thailand
| | - M. Sendhil Kumaran
- Department of Dermatology Postgraduate Institute of Medical Education and Research Chandigarh India
| | | | - Hilary J. Longhurst
- Department of Immunology Addenbrookes Hospital Cambridge University NHS Foundation Trust Cambridge UK
- UCLH London UK
- Addenbrooke's Hospital Cambridge and University College Hospital London UK
| | - William Lumry
- Allergy/Immunology Division Department of Internal Medicine University of Texas Southwestern Medical School Dallas TX USA
| | - Andrew MacGinnitie
- Division of Immunology Department of Pediatrics Boston Children’s Hospital Harvard Medical School Boston MA USA
| | - Markus Magerl
- Department of Dermatology and Allergy Dermatological Allergology Allergie‐Centrum‐Charité Charité—Universitätsmedizin Berlin Berlin Germany
| | - Michael P. Makris
- Allergy Unit “D. Kalogeromitros” 2nd Department of Dermatology and Venereology University Hospital “Attikon”, National and Kapodistrian University of Athens Athens Greece
| | | | - Alexander Marsland
- Department of Dermatology The Urticaria Clinic Salford Royal Foundation Trust University of Manchester Manchester UK
| | | | - Iris V. Medina
- Allergy and Clinical Immunology Department Centro Médico Vitae de Julio Argentina
| | - Raisa Meshkova
- Department of Clinical Immunology and Allergology Smolensk State Medical University Smolensk Russian Federation
| | - Martin Metz
- Department of Dermatology and Allergy Dermatological Allergology Allergie‐Centrum‐Charité Charité—Universitätsmedizin Berlin Berlin Germany
| | - Iman Nasr
- Adult Immunology and Allergy Unit Department of Medicine Royal Hospital Muscat Oman
| | - Jan Nicolay
- Klinik für Dermatologie Universitätsklinikum Mannheim Mannheim Germany
| | - Chikako Nishigori
- Division of Dermatology Kobe University Graduate School of Medicine Kobe Japan
| | - Isao Ohsawa
- Department of Internal Medicine Saiyu Soka Hospital Soka Japan
| | - Kemal Özyurt
- Department of Dermatology Faculty of Medicine Kırşehir Ahi Evran University Kırşehir Turkey
| | | | - Claudio A. S. Parisi
- Adults and Pediatrics Allergy Unit Hospital Italiano de Buenos Aires Buenos Aires Argentina
| | | | - Wolfgang Pfützner
- Department of Dermatology and Allergology Allergy Center Hessen University Clinic Marburg Marburg Germany
| | - Todor Popov
- University Hospital Sv. Ivan Rilski Sofia Bulgaria
| | - Nieves Prior
- Allergy Department Hospital Universitario Severo Ochoa Madrid Spain
| | - German D. Ramon
- Instituto de Alergia e Inmunologia del Sur Buenos Aires Argentina
| | - Adam Reich
- Department of Dermatology University of Rzeszow Rzeszów Poland
| | - Avner Reshef
- Angioedema Center Barzilai Medical Center Ashkelon Israel
| | - Marc A. Riedl
- Department of Medicine University of California—San Diego La Jolla CA USA
| | - Bruce Ritchie
- Departments of Medicine and Medical Oncology University of Alberta Edmonton AB Canada
| | - Heike Röckmann‐Helmbach
- Department of Dermatology and Allergology University Medical Center Utrecht Utrecht The Netherlands
| | | | - Andaç Salman
- Dermatology Department Marmara University School of Medicine Pendik Research and Training Hospital Istanbul Turkey
| | - Mario Sanchez‐Borges
- Allergy and Clinical Immunology Department Centro Medico Docente La Trinidad Caracas Venezuela
| | | | - Faradiba S. Serpa
- Hospital Santa Casa de Misericórdia de Vitória Espírito Santo Brazil
| | | | - Farrukh R. Sheikh
- Department of Medicine King Faisal Specialist Hospital & Research Center Riyadh Saudi Arabia
| | - William Smith
- Clinical Immunology and Allergy Royal Adelaide Hospital Adelaide SA Australia
| | - Angèle Soria
- Service de Dermatologie et Allergologie Hopital Tenon APHP Sorbonne Université Paris France
| | - Petra Staubach
- Department of Dermatology University Medical Center Mainz Germany
| | - Urs C. Steiner
- Department of Clinical Immunology University Hospital Zurich Zurich Switzerland
| | - Marcin Stobiecki
- Department of Environmental Allergology Jagiellonian University Medical College Kraków HAE Center University Hospital Kraków Poland
| | - Gordon Sussman
- Division of Allergy and Immunology University of Toronto Toronto ON Canada
| | - Anna Tagka
- First Department of Dermatology and Venereology National and Kapodistrian University of Athens, "A. Syggros" Hospital Referral Center of Occupational Dermatological Diseases Athens Greece
| | | | - Regina Treudler
- Department of Dermatology, Venerology and Allergology and Leipzig Interdisciplinary Center of Allergology—Comprehensive Allergy Center UMC Leipzig Leipzig Germany
| | - Solange Valle
- Federal University of Rio de Janeiro Rio de Janeiro Brazil
| | - Martijn Doorn
- Department of Dermatology Erasmus MC Rotterdam The Netherlands
| | - Lilian Varga
- 3rd Department of Internal Medicine Hungarian Angioedema Reference Center Semmelweis University Budapest Hungary
| | | | - Nicola Wagner
- Department of Dermatology University of Erlangen Erlangen Germany
| | - Liangchun Wang
- Dermatology Department of Sun Yat‐sen Memorial Hospital Guangzhou China
| | | | - Young‐Min Ye
- Department of Allergy and Clinical Immunology Ajou University School of Medicine Suwon Korea
| | - Anna Zalewska‐Janowska
- Chair of Clinical Immunology and Rheumatology Department of Psychodermatology Medical University of Lodz Lodz Poland
| | - Andrea Zanichelli
- Department of Biomedical and Clinical Sciences Luigi Sacco Hospital University of Milan Milan Italy
| | - Zuotao Zhao
- Department of Dermatology and Venereology First Hospital Peking University Beijing China
- Beijing Key Laboratory of Molecular Diagnosis on Dermatoses Beijing China
| | - Yuxiang Zhi
- Department of Allergy Peking Union Medical College Hospital & Chinese Academy of Medical Sciences Beijing China
| | - Torsten Zuberbier
- Department of Dermatology and Allergy Allergie‐Centrum‐Charité Charité—Universitätsmedizin Berlin Berlin Germany
| | - Ricardo D. Zwiener
- Servicio de Alergia e Inmunología Hospital Universitario Austral Buenos Aires Argentina
| | | |
Collapse
|
19
|
Sagiv M, Slobodin G, Khatib T, Rosner I, Rozenbaum M, Peri R, Sabbah F, Adawi M, Kessel A. AB0119 SERUM LEVELS OF INTERLEUKIN-22 ARE HIGH IN ANKYLOSING SPONDYLITIS, PARTICULARLY IN SMOKERS, BUT DO NOT CORRELATE WITH RADIOGRAPHIC BONE FORMATION NOR WITH DISEASE ACTIVITY. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.2961] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Elevated serum levels of interleukin (IL)-22 were reported in patients with ankylosing spondylitis (AS).[1]IL-22 was also reported to drive the osteogenic differentiation of mesenchymal stem cells.[2]Objectives:To confirm the fact that serum levels of IL-22 are elevated in AS patients and to examine the relationship between concentrations of IL-22 and degree of radiographic progression in AS patients.Methods:Seventeen male patients with established AS of more than 4 years duration signed the informed consent and donated 10 ml of peripheral blood. Demographic data was collected from patient’s charts. Disease activity indices were calculated for all patients and radiographic disease progression was calculated as mSASS. A control group included 6 healthy persons and 4 patients with advanced diffuse idiopathic skeletal hyperostosis (DISH). Serum levels of IL-22 were tested using enzyme-linked immunosorbent assay. Intergroup differences were examined using the Mann-Whitney test, while correlations were calculated using Pearson correlation coefficient.Results:Serum IL-22 levels were remarkably elevated in patients with AS, comparing to healthy individuals and patients with DISH (p=0.005). However, increased concentrations of IL-22 did not correlate with the degree of radiographic progression or AS disease activity indices, nor with disease duration or patient’s age. Presence of diarrhea, psoriasis, uveitis, or elevated levels of C-reactive protein did not influence the levels of IL-22 as well. More AS patients with elevated serum IL-22 were smokers (p=0.05).Fig. 1.Serum levels of interleukin 22 (pg/ml)Conclusion:The serum levels of IL-22 are elevated in patients with AS. It seems that smoking can be related to the elevated levels of serum IL-22 in AS. The significance of this data is unclear and further research is needed.References:[1]Zhang L, Li Y gang, Li Y hua, Qi L, Liu X guang, Yuan C zhong, et al. Increased frequencies of th22 cells as well as th17 cells in the peripheral blood of patients with ankylosing spondylitis and rheumatoid arthritis. PLoS One. 2012;7(4).[2]El-Zayadi AA, Jones E, Churchman S, Baboolal T, Cuthbert R, El-Jawhari J, et al. Interleukin-22 drives the proliferation, migration and osteogenic differentiation of mesenchymal stem cells: a novel cytokine that could contribute to new bone formation in spondyloarthropathies. Rheumatology. 2016 Dec 10;56.Disclosure of Interests:None declared
Collapse
|
20
|
Genizi J, Halevy A, Schertz M, Osman K, Assaf N, Segal I, Srugo I, Kessel A, Engel-Yeger B. Sensory processing patterns affect headache severity among adolescents with migraine. J Headache Pain 2020; 21:48. [PMID: 32375649 PMCID: PMC7203579 DOI: 10.1186/s10194-020-01119-0] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2020] [Accepted: 04/28/2020] [Indexed: 01/03/2023] Open
Abstract
Objective To evaluate the relationship between pain catastrophizing level, sensory processing patterns, and headache severity among adolescents with episodic migraine. Background Catastrophizing about pain is a critical variable in how we understand adjustment to pain and has a unique contribution in predicting pain intensity. Recent reports found that migraine is also related to enhanced sensory sensitivity. However, the relationship between pain severity, pain catastrophizing level and sensory sensitivity requires greater study especially among adolescents. Methods Participants were 92 adolescents aged 13–18 years, 40 with episodic migraine and 52 healthy controls. The migraine patients were prospectively recruited from outpatient pediatric neurology clinics. All participants completed the Adolescent/Adult Sensory Profile (AASP), and the Pain Catastrophizing Scale for children (PCS-ch). The migraine groups also completed the PedMIDAS, which measures Headache related disability. Results Adolescents with migraine had significantly lower tendency to seek sensory input than healthy controls. Elevated rumination and helplessness correlated with higher migraine pain severity. Tendency to avoid sensory input predicted the migraine related disability level. They also significantly higher pain catastrophizing level than healthy controls, as seen in enhanced rumination (p ≤ 0.001) and helplessness (p ≤ 0.05). Conclusions Sensory processing difficulties are common among adolescents with episodic migraine. Sensory avoidance may be related to pain experience, and pain catastrophizing and disability level. Trial registration ISRCTN ISRCTN73824458. Registered 28 September 2014. retrospectively registered.
Collapse
Affiliation(s)
- Jacob Genizi
- Pediatric Neurology Unit, Bnai Zion Medical Center, Haifa, Israel. .,Department of Pediatrics, Bnai Zion Medical Center, Haifa, Israel. .,Bruce and Ruth Rappaport Faculty of Medicine, Technion, Haifa, Israel.
| | - Ayelet Halevy
- Department of Pediatric Neurology, Schneider Children's Medical Center, Petach Tikva, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Mitchell Schertz
- Bruce and Ruth Rappaport Faculty of Medicine, Technion, Haifa, Israel.,Child Development and Pediatric Neurology Service, Meuhedet-Northern Region, Haifa, Israel
| | - Khaled Osman
- Department of Pediatrics, Bnai Zion Medical Center, Haifa, Israel
| | - Nurit Assaf
- Pediatric Neurology Unit, Bnai Zion Medical Center, Haifa, Israel.,Department of Pediatrics, Bnai Zion Medical Center, Haifa, Israel.,Bruce and Ruth Rappaport Faculty of Medicine, Technion, Haifa, Israel
| | - Idan Segal
- Pediatric Neurology Unit, Bnai Zion Medical Center, Haifa, Israel.,Department of Pediatrics, Bnai Zion Medical Center, Haifa, Israel
| | - Isaac Srugo
- Department of Pediatrics, Bnai Zion Medical Center, Haifa, Israel.,Bruce and Ruth Rappaport Faculty of Medicine, Technion, Haifa, Israel
| | - Aharon Kessel
- Bruce and Ruth Rappaport Faculty of Medicine, Technion, Haifa, Israel.,Division of Allergy and Clinical Immunology, Bnai Zion Medical Center, Haifa, Israel
| | | |
Collapse
|
21
|
Epov L, Garkaby J, Almog M, Ben-Or O, Schichter-Konfino V, Toker O, Bamberger E, Kessel A. Using skin prick test to sesame paste in the diagnosis of sesame seed allergy. J Allergy Clin Immunol Pract 2019; 8:1456-1458. [PMID: 31730914 DOI: 10.1016/j.jaip.2019.10.038] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/26/2019] [Revised: 10/26/2019] [Accepted: 10/28/2019] [Indexed: 11/17/2022]
Affiliation(s)
- Larisa Epov
- Division of Allergy & Clinical Immunology, Bnai Zion Medical Center, Rappaport Faculty of Medicine, Technion, Haifa, Israel
| | - Jenny Garkaby
- Division of Allergy & Clinical Immunology, Bnai Zion Medical Center, Rappaport Faculty of Medicine, Technion, Haifa, Israel
| | - Meital Almog
- Division of Allergy & Clinical Immunology, Bnai Zion Medical Center, Rappaport Faculty of Medicine, Technion, Haifa, Israel
| | - Orly Ben-Or
- Department of Pediatrics, Carmel Medical Center, Rappaport Faculty of Medicine, Technion, Haifa, Israel
| | - Vered Schichter-Konfino
- Department of Pediatrics, Hillel Yaffe Medical Center, Hadera, Israel; Rappaport Faculty of Medicine, Technion, Haifa, Israel
| | - Ori Toker
- Allergy and Clinical Immunology Clinic, Department of Pediatrics, Shaare Zedek Medical Center, Hadassah-Hebrew University Medical School, Jerusalem, Israel
| | - Ellen Bamberger
- Department of Pediatrics, Bnai Zion Medical Center, Rappaport Faculty of Medicine, Technion, Haifa, Israel
| | - Aharon Kessel
- Division of Allergy & Clinical Immunology, Bnai Zion Medical Center, Rappaport Faculty of Medicine, Technion, Haifa, Israel.
| |
Collapse
|
22
|
Reshef A, Grivcheva-Panovska V, Kessel A, Kivity S, Klimaszewska-Rembiasz M, Moldovan D, Farkas H, Gutova V, Fritz S, Relan A, Giannetti B, Magerl M. Recombinant human C1 esterase inhibitor treatment for hereditary angioedema attacks in children. Pediatr Allergy Immunol 2019; 30:562-568. [PMID: 30993784 PMCID: PMC6851822 DOI: 10.1111/pai.13065] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/04/2018] [Revised: 04/02/2019] [Accepted: 04/04/2019] [Indexed: 12/14/2022]
Abstract
BACKGROUND Attacks of hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency (C1-INH-HAE) usually begin during childhood or adolescence. However, limited data are available regarding indications and modalities of treatment of children. This study evaluated recombinant human C1-INH (rhC1-INH) for HAE attacks in children. METHODS This open-label, phase 2 study included children aged 2-13 years with C1-INH-HAE. Eligible HAE attacks were treated intravenously with rhC1-INH 50 IU/kg body weight (maximum, 4200 IU). The primary end-point was time to beginning of symptom relief (TOSR; ≥20 mm decrease from baseline in visual analog scale [VAS] score, persisting for two consecutive assessments); secondary end-point was time to minimal symptoms (TTMS; <20 mm VAS score for all anatomic locations). RESULTS Twenty children (aged 5-14 years; 73 HAE attacks) were treated with rhC1-INH. Seventy (95.9%) of the attacks were treated with a single dose of rhC1-INH. Seven (35.0%) children were treated for four or more attacks. Overall, median TOSR was 60.0 minutes (95% confidence interval [CI], 60.0-65.0); data were consistent across attacks. Median TTMS was 122.5 minutes (95% CI, 120.0-126.0); data were consistent across attacks. No children withdrew from the study due to adverse events. No treatment-related serious adverse events or hypersensitivity reactions were reported; no neutralizing antibodies were detected. CONCLUSIONS Recombinant human C1-INH was efficacious, safe, and well tolerated in children. Data support use of the same dosing regimen for HAE attacks in children (50 IU/kg; up to 4200 IU, followed by an additional dose, if needed) as is currently recommended for adolescents and adults.
Collapse
Affiliation(s)
| | | | - Aharon Kessel
- Technion Faculty of Medicine, Bnai Zion Medical Center, Haifa, Israel
| | | | | | | | | | - Vaclava Gutova
- Institute of Immunology and Allergology, Pilsen, Czech Republic
| | | | - Anurag Relan
- Pharming Healthcare Inc., Bridgewater, New Jersey, USA
| | | | | |
Collapse
|
23
|
Genizi J, Halevy A, Schertz M, Osman K, Assaf N, Segal I, Srugo I, Kessel A, Engel-Yeger B. Sensory Processing Difficulties Correlate With Disease Severity and Quality of Life Among Children With Migraine. Front Neurol 2019; 10:448. [PMID: 31178812 PMCID: PMC6543047 DOI: 10.3389/fneur.2019.00448] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2018] [Accepted: 04/12/2019] [Indexed: 01/03/2023] Open
Abstract
Introduction: Headaches are common among children and about 80% of children reporting them. Migraine and tension type headaches are the most common primary headaches in children and the prevalence of migraine is about 8%. Accompanying sensory symptoms are common before, during and after migraine attacks. They may be a part of a wider symptom constellation called sensory processing disorder or difficulties (SPD). This includes both hyper or hypo sensitivity to sensations. However, the literature regarding sensory processing symptoms of children and youth with headaches as well as its interaction with child's emotional aspects and quality of life is scarce. Materials and Methods: One hundred and thirty-four children between the ages of 8 and 12 participated in this study. Fifty-four children (22 boys and 32 girls) with episodic migraine were prospectively recruited from pediatric neurological clinics during the years 2014-2017. The control group included 80 healthy children. Both groups completed a health and demographic questionnaire, headache assessment including Ped-MIDAS, Short Sensory Profile, State-Trait Anxiety Inventory (STAI) for children, and the Pediatric Quality of Life Inventory. Results: Children with migraine showed significantly higher prevalence of sensory processing difficulties and lower quality of life compared to healthy controls. Among children with migraine, sensory processing difficulties significantly correlated with lower quality of life. Headache-related disability and sensory processing difficulties predicted quality of life. Conclusion: The possible relationship between migraine and sensory processing disorder or difficulties stresses the need to screen for sensory processing difficulties among children with migraine and when found-refer to their impacts on children's daily function and quality of life.
Collapse
Affiliation(s)
- Jacob Genizi
- Pediatric Neurology Unit, Bnai Zion Medical Center, Haifa, Israel.,Department of Pediatrics, Bnai Zion Medical Center, Haifa, Israel.,Bruce and Ruth Rappaport Faculty of Medicine, Technion, Haifa, Israel
| | - Ayelet Halevy
- Department of Pediatric Neurology, Petach Tikva, Sackler Faculty of Medicine, Schneider Children's Medical Center, Tel Aviv University, Tel Aviv, Israel
| | - Mitchell Schertz
- Bruce and Ruth Rappaport Faculty of Medicine, Technion, Haifa, Israel.,Child Development and Pediatric Neurology Service, Meuhedet-Northern Region, Haifa, Israel
| | - Khaled Osman
- Department of Pediatrics, Bnai Zion Medical Center, Haifa, Israel
| | - Nurit Assaf
- Pediatric Neurology Unit, Bnai Zion Medical Center, Haifa, Israel.,Department of Pediatrics, Bnai Zion Medical Center, Haifa, Israel.,Bruce and Ruth Rappaport Faculty of Medicine, Technion, Haifa, Israel
| | - Idan Segal
- Pediatric Neurology Unit, Bnai Zion Medical Center, Haifa, Israel.,Department of Pediatrics, Bnai Zion Medical Center, Haifa, Israel
| | - Isaac Srugo
- Department of Pediatrics, Bnai Zion Medical Center, Haifa, Israel.,Bruce and Ruth Rappaport Faculty of Medicine, Technion, Haifa, Israel
| | - Aharon Kessel
- Bruce and Ruth Rappaport Faculty of Medicine, Technion, Haifa, Israel.,Division of Allergy and Clinical Immunology, Bnai Zion Medical Center, Haifa, Israel
| | | |
Collapse
|
24
|
Fireman Klein E, Adir Y, Krencel A, Peri R, Vasserman B, Fireman E, Kessel A. Ultrafine particles in airways: a novel marker of COPD exacerbation risk and inflammatory status. Int J Chron Obstruct Pulmon Dis 2019; 14:557-564. [PMID: 30880945 PMCID: PMC6402613 DOI: 10.2147/copd.s187560] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Purpose Ultrafine particles (UFP) are toxic due to their small size and penetration into deeper lung compartments. We aimed to evaluate the exhaled breath condensate (EBC)-UFP content as a reflection of inflammation and oxidative stress status in COPD patients and as an exacerbation risk marker. Methods EBC was collected by conventional methods. Particles were analyzed with NanoSight LM20. EBC carbonyl and 8-hydroxydeoxyguanosine (8-OHdG) levels were measured using ELISA kits. Study population (58 COPD patients and 40 healthy smoker and non-smoker controls) underwent spirometry, diffusion capacity, EBC testing, and blood sampling. Results Absolute eosinophil count, C-reactive protein (CRP), and lactate dehydrogenase in serum were elevated in the COPD group compared with the controls (224 U/L, 5 mg/L, and 391 U/L vs 154 U/L, 3 mg/L, and 330 U/L, P=0.009, P=0.05, and P=0.004, respectively). COPD patients had lower UFP concentrations in EBC compared with controls (0.24 E8/mL vs 0.51 E8/mL, P≤0.001). A mirror image was detected in serum: COPD patients had higher UFP concentrations compared with controls (9.8 E8/mL vs 6.7 E8/mL, respectively, P=0.03). EBC carbonyl and 8-OHdG levels were higher among COPD patients compared with controls (5.1 per 1 µg/mL protein and 0.036 ng/mL vs 0.41 per 1 µg/mL protein and 0.003 ng/mL, P=0.001 and P≤0.001, respectively). EBC UFP concentrations were negatively correlated with pack years (R=−0.44, P ≤0.001) and positively correlated with FEV1 and diffusing lung capacity for carbon monoxide (R=0.46, 0.23, P ≤0.001 and P=0.04, respectively). Low EBC UFP concentrations (≤0.18 E8/mL) and CRP levels ≥5 mg/L were independent predictors of the frequent exacerbator phenotype (OR 3.6; 95% CI: 1.06–7.97; P=0.04 and OR 4.4; 95% CI: 1.24–10.2; P=0.02, respectively). Conclusion UFP content in EBC reflects the inflammatory state of airways. Low UFP concentrations in EBC and high in serum of COPD patients support our hypothesis that increased epithelial permeability could be the mechanism behind those findings.
Collapse
Affiliation(s)
- Einat Fireman Klein
- Pulmonary Division, Carmel Medical Center, Rappaport Faculty of Medicine, Technion - Institute of Technology, Haifa, Israel,
| | - Yochai Adir
- Pulmonary Division, Carmel Medical Center, Rappaport Faculty of Medicine, Technion - Institute of Technology, Haifa, Israel,
| | - Amir Krencel
- Division of Allergy and Clinical Immunology, Bnai Zion Medical Center, Rappaport Faculty of Medicine, Technion - Institute of Technology, Haifa, Israel
| | - Regina Peri
- Division of Allergy and Clinical Immunology, Bnai Zion Medical Center, Rappaport Faculty of Medicine, Technion - Institute of Technology, Haifa, Israel
| | - Bella Vasserman
- Division of Allergy and Clinical Immunology, Bnai Zion Medical Center, Rappaport Faculty of Medicine, Technion - Institute of Technology, Haifa, Israel
| | - Elizabeth Fireman
- Institute of Pulmonary Diseases, National Laboratory Service for Interstitial Lung Diseases, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel.,Department of Occupational and Environmental Medicine, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Aharon Kessel
- Division of Allergy and Clinical Immunology, Bnai Zion Medical Center, Rappaport Faculty of Medicine, Technion - Institute of Technology, Haifa, Israel
| |
Collapse
|
25
|
Ovadia A, Nahum A, Tasher D, Abiri S, Epov L, Kessel A, Dalal I. Sesame: An unrecognized trigger of food protein-induced enterocolitis syndrome. J Allergy Clin Immunol Pract 2019; 7:305-306. [PMID: 29802907 DOI: 10.1016/j.jaip.2018.05.007] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/15/2018] [Revised: 04/22/2018] [Accepted: 05/03/2018] [Indexed: 10/16/2022]
Affiliation(s)
- Adi Ovadia
- Pediatric Allergy Unit, E. Wolfson Medical Center, Holon, Israel; Department of Pediatrics, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Pediatrics, E. Wolfson Medical Center, Holon, Israel.
| | - Amit Nahum
- Pediatrics Department A, Saban Pediatric Medical Center, Soroka University Medical Center, and Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
| | - Diana Tasher
- Department of Pediatrics, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Pediatrics, E. Wolfson Medical Center, Holon, Israel
| | - Shirli Abiri
- Department of Pediatrics, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Pediatrics, E. Wolfson Medical Center, Holon, Israel
| | - Larisa Epov
- Division of Allergy and Clinical Immunology, Bnai Zion Medical Center, Technion Faculty of Medicine, Haifa, Israel
| | - Aharon Kessel
- Division of Allergy and Clinical Immunology, Bnai Zion Medical Center, Technion Faculty of Medicine, Haifa, Israel
| | - Ilan Dalal
- Pediatric Allergy Unit, E. Wolfson Medical Center, Holon, Israel; Department of Pediatrics, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Pediatrics, E. Wolfson Medical Center, Holon, Israel
| |
Collapse
|
26
|
Relan A, Reshef A, Grivcheva-Panovska V, Kessel A, Kivity S, Klimaszewska-Rembiasz M, Moldovan D, Farkas H, Gutova V, Fritz S, Bellizzi L, Giannetti B. PHARMACOKINETICS OF RECOMBINANT HUMAN C1 ESTERASE INHIBITOR FOR TREATMENT OF HEREDITARY ANGIOEDEMA ATTACKS IN CHILDREN. Ann Allergy Asthma Immunol 2018. [DOI: 10.1016/j.anai.2018.09.113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
27
|
Caplunik-Pratsch AL, Potasman I, Kessel A, Paz A. Doxycycline desensitization in chronic Q fever-A critical tool for the clinician. IDCases 2018; 11:70-72. [PMID: 29619325 PMCID: PMC5881519 DOI: 10.1016/j.idcr.2018.01.006] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2017] [Revised: 01/17/2018] [Accepted: 01/17/2018] [Indexed: 10/26/2022] Open
Abstract
We present the case of a 45 year old woman with acute Q fever pneumonia who progressed to the chronic phase of the disease despite azithromycin therapy. A trial of doxycycline was halted because of severe allergy and she was put on clarithromycin and later moxifloxacin. Failure of both drugs required desensitization to doxycycline with escalating doses. After two-year treatment with doxycycline-hydroxychloroquine combination, complete recovery was declared. Our case highlights the option of doxycycline desensitization when an acute allergic reaction poses an obstacle to optimal treatment.
Collapse
Affiliation(s)
- Aila Luise Caplunik-Pratsch
- Infectious Diseases Unit, Bnai-Zion Medical Center, Sderot Eliyahu Golomb 47, Haifa Affiliated with Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
| | - Israel Potasman
- Infectious Diseases Unit, Bnai-Zion Medical Center, Sderot Eliyahu Golomb 47, Haifa Affiliated with Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
| | - Aharon Kessel
- Division of Allergy and Clinical Immunology, Bnai Zion Medical Center, Sderot Eliyahu Golomb 47, Haifa Affiliated with Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
| | - Alona Paz
- Infectious Diseases Unit, Bnai-Zion Medical Center, Sderot Eliyahu Golomb 47, Haifa Affiliated with Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
| |
Collapse
|
28
|
Lidar M, Brantz Y, Shinar Y, Reznik-Wolf H, Livneh A, Ben Zvi I, Cohen R, Berkun Y, Hashkes PJ, Peleg H, Kessel A, Slobodin G, Rozenbaum M, Goldzweig O, Pras E. A high and equal prevalence of the Q703K variant in NLRP3 patients with autoinflammatory symptoms and ethnically matched controls. Clin Exp Rheumatol 2017; 35 Suppl 108:82-85. [PMID: 29148409] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2017] [Accepted: 09/08/2017] [Indexed: 06/07/2023]
Abstract
OBJECTIVES Cryopyrin associated periodic syndromes (CAPS) comprise a spectrum of autoinflammatory disorders of varying severity caused by mutations in the NLRP3 gene. The NLRP3-Q703K allele has been reported both as a functional polymorphism and as a low penetrance mutation. METHODS To describe the clinical phenotype of subjects with the Q703K allele and to report the frequency of this allele among patients with autoinflammatory symptoms and healthy controls. To this end, a cohort of 10 ethnically-matched controls per each Q703K-carrying patient, was composed. RESULTS Ninety patients suspected of harboring a systemic autoinflammatory disease (SAID), exclusive of FMF, were referred to our center for genotyping between 2012 and 2015. Fourteen of them (15.5%) were found to carry the Q703K allele, compared to 22 of 130 (16.9%) healthy, ethnically matched controls. CONCLUSIONS The similar carrier rate of the NLRP3-Q703K allele among patients with manifestations of a SAID and an ethnically matched control group suggest that this variant, does not determine the clinical phenotype. This reiterates the importance of testing a control group to avoid erroneously attributing a causative role to a gene polymorphism.
Collapse
Affiliation(s)
- Merav Lidar
- Sheba Medical Centre, affiliated to the Sackler School of Medicine, Tel Aviv University, Israel
| | - Yael Brantz
- Sheba Medical Centre, affiliated to the Sackler School of Medicine, Tel Aviv University, Israel
| | - Yael Shinar
- Sheba Medical Centre, affiliated to the Sackler School of Medicine, Tel Aviv University, Israel
| | - Haike Reznik-Wolf
- Sheba Medical Centre, affiliated to the Sackler School of Medicine, Tel Aviv University, Israel
| | - Avi Livneh
- Sheba Medical Centre, affiliated to the Sackler School of Medicine, Tel Aviv University, Israel
| | - Ilan Ben Zvi
- Sheba Medical Centre, affiliated to the Sackler School of Medicine, Tel Aviv University, Israel
| | - Rinat Cohen
- Sheba Medical Centre, affiliated to the Sackler School of Medicine, Tel Aviv University, Israel
| | | | | | | | | | | | | | | | - Elon Pras
- Sheba Medical Centre, affiliated to the Sackler School of Medicine, Tel Aviv University, Israel.
| |
Collapse
|
29
|
Kessel A, Farkas H, Kivity S, Veszeli N, Kőhalmi KV, Engel-Yeger B. The relationship between anxiety and quality of life in children with hereditary angioedema. Pediatr Allergy Immunol 2017; 28:692-698. [PMID: 28692169 DOI: 10.1111/pai.12758] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 07/06/2017] [Indexed: 11/29/2022]
Abstract
BACKGROUND The severe life-threatening characteristics of hereditary angioedema (HAE) with C1-inhibitor deficiency (C1-INH-HAE) can affect anxiety levels among pediatric patients. This emotional burden together with the physical restrictions of C1-INH-HAE may decrease children's health-related quality of life (HRQoL). OBJECTIVES (i) To compare anxiety state and trait between children with C1-INH-HAE and healthy controls; (ii) to examine the relationship between the level of anxiety of children with C1-INH-HAE, their disease activity/affected sites and their HRQoL; and (iii) to predict the HRQoL of children with C1-INH-HAE based on their anxiety level and disease activity/affected sites METHODS: Thirty-three children with C1-INH-HAE (aged 5-18 years) and 52 healthy controls were recruited from Israel and Hungary. All children completed the State-Trait Anxiety Inventory for Children (STAIC), the Pediatric Quality of Life Inventory (Peds-QL) demographic questionnaire and a disease activity and site questionnaire . Disease activity was defined as the number of attacks in last year. RESULTS Both anxiety state and trait were significantly higher among children with C1-INH-HAE as compared to the controls (44.74±10.56 vs 38.76±10.67, P<.01, 29.21±5.16 vs 25.23±4.09, P<.001 in comparison). Significant differences were found between C1-INH-HAE patients with HAE attacks, asymptomatic C1-INH-HAE patients, and healthy controls in both anxiety state (F56,2 =4.69, P=.001) and trait (F56,2 =9.06, P<.0001). A higher anxiety trait was correlated with the number of angioedema-affected sites (r=.52, P=.003). The presence of HAE attacks and higher anxiety trait predicted a lower HRQoL in children with C1-INH-HAE. CONCLUSIONS C1-INH-HAE children have higher anxiety trait and state, which correlate with reduced HRQoL domains.
Collapse
Affiliation(s)
- Aharon Kessel
- Division of Allergy and Clinical Immunology, Bnai Zion Medical Center, Technion Faculty of Medicine, Haifa, Israel
| | - Henriette Farkas
- 3rd Department of Internal Medicine, Hungarian Angioedema Center, Semmelweis University, Budapest, Hungary
| | - Shmuel Kivity
- Allergy Department, Tel-Aviv Sourasky Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Nóra Veszeli
- 3rd Department of Internal Medicine, Hungarian Angioedema Center, Semmelweis University, Budapest, Hungary
| | - Kinga V Kőhalmi
- 3rd Department of Internal Medicine, Hungarian Angioedema Center, Semmelweis University, Budapest, Hungary
| | - Batya Engel-Yeger
- Occupational Therapy Department, Faculty of Social Welfare and Health Sciences, University of Haifa, Haifa, Israel
| |
Collapse
|
30
|
Vadasz Z, Tal Y, Rotem M, Shichter-Confino V, Mahlab-Guri K, Graif Y, Kessel A, Agmon-Levin N, Maoz-Segal R, Kivity S, Benor S, Lachover-Roth I, Zeldin Y, Stein M, Toker O, Hassoun G, Bezalel-Rosenberg S, Toubi E, Asher I, Sthoeger Z. Omalizumab for severe chronic spontaneous urticaria: Real-life experiences of 280 patients. J Allergy Clin Immunol Pract 2017; 5:1743-1745. [PMID: 28988786 DOI: 10.1016/j.jaip.2017.08.035] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/28/2017] [Revised: 08/22/2017] [Accepted: 08/28/2017] [Indexed: 10/18/2022]
Affiliation(s)
- Zahava Vadasz
- Division of Allergy and Clinical Immunology, Bnai-Zion Medical Center, Haifa, Israel.
| | - Yuval Tal
- Allergy Unit, Hadassah Medical Center, Jerusalem, Israel
| | | | | | - Keren Mahlab-Guri
- Division of Allergy, Clinical Immunology and AIDS, Kaplan Medical Center, Rehovot, Israel
| | - Yael Graif
- Allergy Unit, Rabin Medical Center, Petach-Tikva, Israel
| | - Aharon Kessel
- Division of Allergy and Clinical Immunology, Bnai-Zion Medical Center, Haifa, Israel
| | - Nancy Agmon-Levin
- Allergy and Clinical Immunology, Sheba Medical Center, Tel-Aviv, Israel
| | - Ramit Maoz-Segal
- Allergy and Clinical Immunology, Sheba Medical Center, Tel-Aviv, Israel
| | - Shmuel Kivity
- Allergy Unit, Sourasky Medical Center, Tel-Aviv, Israel
| | - Shira Benor
- Allergy Unit, Sourasky Medical Center, Tel-Aviv, Israel
| | | | - Yuri Zeldin
- Allergy and Clinical Immunology Unit, Clalit Health Services, Southern District, Israel
| | - Migel Stein
- Allergy Unit, Wolfson Medical Center, Holon, Israel
| | - Ori Toker
- Allergy Unit, Hadassah Medical Center, Jerusalem, Israel
| | - Gamal Hassoun
- Division of Allergy, Clinical Immunology and AIDS, Rambam Medical Center, Haifa, Israel
| | | | - Elias Toubi
- Division of Allergy and Clinical Immunology, Bnai-Zion Medical Center, Haifa, Israel
| | - Ilan Asher
- Division of Allergy, Clinical Immunology and AIDS, Kaplan Medical Center, Rehovot, Israel
| | - Zev Sthoeger
- Division of Allergy, Clinical Immunology and AIDS, Kaplan Medical Center, Rehovot, Israel
| | | |
Collapse
|
31
|
Levin Agmon N, Kessel A, Maoz Segal R, Rottem M, Tal Y, Confino-Cohen R, Tobi E. [RECOMMENDATION FOR EVALUATION AND TREATMENT OF CHRONIC URTICARIA - THE ISRAELI ASSOCIATION FOR ALLERGY AND CLINICAL IMMUNOLOGY]. Harefuah 2017; 156:385-389. [PMID: 28661105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
Chronic urticaria is a disease manifested by a pruritic rash lasting longer than 6 weeks that may severely affect quality of life and daily function. Chronic urticaria can be further divided into chronic spontaneous urticaria which appears without a trigger and chronic inducible urticaria which evolves following distinct physical triggers. These two clinical manifestations could coexist in the same patient. The pathogenesis of chronic urticaria is not fully elucidated, although it is considered an autoimmune disease in at least 50% patients that produce auto- IgG antibodies targeted against the high affinity Fc receptor and to a lesser extent against IgE itself. Auto-antibodies associated with different autoimmune diseases can be detected such as those directed at thyroid proteins. Urticaria tends to spontaneously resolve in 50% of patients within the first year while others will suffer from it for a much longer period of time. The treatment of chronic urticaria has dramatically progressed in the last decade, enabling reduction of systemic corticosteroid use which has been the cornerstone of treatment in the past. The recommended treatment for chronic urticaria is currently based on a stepwise approach that enables achieving disease control with a reasonably good quality of life. The first step of the treatment ladder consists of selective, new generation, anti-H1 histamine blockers, which do not cross the blood brain barrier, starting from the recommended dose (first line) and increasing up to four-fold (second line). The third line of treatment is the addition of immune modulators such as leukotriene receptor blockers (Singulair), anti-IgE biological therapy (Xolair), or cyclosporine. In this review we present the updates and considerations arising during evaluation and treatment of chronic urticaria. The need for specific tests, immunologist/allergologist evaluation, as well as treatment modalities taking into consideration the large body of evidence that has accumulated in the last few years, the new international guidelines as well as their application in Israel have been addressed.
Collapse
Affiliation(s)
- Nancy Levin Agmon
- Allergy, Immunology and Angioedema Unit, Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center (affiliated to Tel-Aviv University)
| | - Aharon Kessel
- Division of Allergy and Clinical Immunology, Bnai Zion Medical Center (affiliated to the Technion Medicine Faculty)
| | - Ramit Maoz Segal
- Allergy, Immunology and Angioedema Unit, Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center
| | - Menachem Rottem
- Allergy and Clinical Unit, HaEmek Medical Center (affiliated to the Technion Medicine Faculty)
| | - Yuval Tal
- Allergy and Clinical Immunology Unit, Medicine Department, Hadassah University Medical Center (affiliated to the Hebrew University Medicine Faculty)
| | - Ronit Confino-Cohen
- Allergy and Clinical Immunology Unit, Meir Medical Center (affiliated to Tel-Aviv University Medicine Faculty)
| | - Elias Tobi
- Division of Allergy and Clinical Immunology, Bnai Zion Medical Center (affiliated to the Technion Medicine Faculty)
| |
Collapse
|
32
|
Engel-Yeger B, Farkas H, Kivity S, Veszeli N, Kőhalmi KV, Kessel A. Health-related quality of life among children with hereditary angioedema. Pediatr Allergy Immunol 2017; 28:370-376. [PMID: 28258590 DOI: 10.1111/pai.12712] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 02/27/2017] [Indexed: 11/28/2022]
Abstract
BACKGROUND The clinical expressions of hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) and its related burden may negatively affect patient quality of life. This study aimed to assess health-related quality of life (HRQoL) in children with C1-INH-HAE. METHODS Children (N = 98: 34 C1-INH-HAE patients, 64 healthy controls) aged 3-18 years were recruited in Israel and Hungary. All individuals completed a demographic questionnaire, a disease activity and site questionnaire, and the Pediatric Quality of Life Inventory (PedsQL™) 4.0 Generic Core Scales (child self-report and maternal proxy report) to assess HRQoL. RESULTS Among C1-INH-HAE patients, nine (26.5%) had 1-5 attacks/year, six (17.6%) had 6-18 attacks/year, eight (23.5%) had 25-60 attacks/year, and 11 (32.4%) were asymptomatic over the previous year. Children with C1-INH-HAE attacks demonstrated lower HRQoL than healthy control children across the total score, school, and psychosocial dimensions of the PedsQL™. The number of C1-INH-HAE attacks negatively correlated with the total HRQoL score (r = -0.48, p = 0.008), school-related HRQoL (r = -0.39, p = 0.02), and psychosocial HRQoL (r = -0.43, p = 0.01). Patients with multisite laryngeal, abdominal, and peripheral C1-INH-HAE attacks had a lower HRQoL compared with those who experienced solely peripheral attacks across the total score (p = 0.04), physical (p = 0.04), and school (p = 0.02) domains. There was no significant difference between asymptomatic C1-INH-HAE patients and healthy controls. CONCLUSIONS Children with symptomatic C1-INH-HAE demonstrate impaired HRQoL compared with healthy controls. HRQoL was affected by the frequency and site of C1-INH-HAE attacks and mostly in the school and physical domains.
Collapse
Affiliation(s)
- Batya Engel-Yeger
- Department Faculty of Social Welfare and Health Sciences, University of Haifa Occupational Therapy, Haifa, Israel
| | - Henriette Farkas
- 3rd Department of Internal Medicine, Hungarian Angioedema Center, Semmelweis University, Budapest, Hungary
| | - Shmuel Kivity
- Allergy Department, Tel-Aviv Sourasky Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Nóra Veszeli
- 3rd Department of Internal Medicine, Hungarian Angioedema Center, Semmelweis University, Budapest, Hungary
| | - Kinga Viktória Kőhalmi
- 3rd Department of Internal Medicine, Hungarian Angioedema Center, Semmelweis University, Budapest, Hungary
| | - Aharon Kessel
- Division of Allergy and Clinical Immunology, Technion Faculty of Medicine, Bnai Zion Medical Center, Haifa, Israel
| |
Collapse
|
33
|
Kessel A, Lin C, Vadasz Z, Peri R, Eiza N, Berkowitz D. The association between semaphorin 3A levels and gluten-free diet in patients with celiac disease. Clin Immunol 2017; 184:73-76. [PMID: 28502679 DOI: 10.1016/j.clim.2017.05.010] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2016] [Revised: 04/10/2017] [Accepted: 05/10/2017] [Indexed: 12/20/2022]
Abstract
Celiac disease (CD) is an inflammatory disease affecting the small intestine. We aim to assess serum level and expression of semaphorin 3A (Sema3A) on T regulatory (Treg) cells in CD patients. Twenty-six newly diagnosed celiac patients, 13 celiac patients on a gluten-free diet and 16 healthy controls included in the study. Sema3A protein level in the serum of celiac patients was significantly higher compared to healthy group (7.17±1.8ng/ml vs. 5.67±1.5ng/ml, p=0.012). Sema3A expression on Treg cells was statistically lower in celiac patients compared to healthy subjects (p=0.009) and significantly lower in celiac patients compared to celiac patients on gluten free diet (p=0.04). Negative correlation was found between Sema3A on Teg cells and the level of IgA anti-tTG antibodies (r=-0.346, p<0.01) and anti-DGP (r=-0.448, p<0.01). This study suggests involvement of the Sema3A in the pathogenesis of CD.
Collapse
Affiliation(s)
- Aharon Kessel
- Division of Allergy and Clinical Immunology, Bnai Zion Medical Center, Technion Faculty of Medicine, Haifa, Israel.
| | - Chen Lin
- Division of Allergy and Clinical Immunology, Bnai Zion Medical Center, Technion Faculty of Medicine, Haifa, Israel
| | - Zahava Vadasz
- Division of Allergy and Clinical Immunology, Bnai Zion Medical Center, Technion Faculty of Medicine, Haifa, Israel
| | - Regina Peri
- Division of Allergy and Clinical Immunology, Bnai Zion Medical Center, Technion Faculty of Medicine, Haifa, Israel
| | - Nasren Eiza
- Division of Allergy and Clinical Immunology, Bnai Zion Medical Center, Technion Faculty of Medicine, Haifa, Israel
| | - Drora Berkowitz
- Division of Pediatric Gastroenterology, Bnai Zion Medical Center, Faculty of Medicine, Technion, Haifa, Israel
| |
Collapse
|
34
|
Storch S, Willner N, Toubi A, Croitoru S, Wolfson V, Matar I, Grushka E, Odeh M, Wolfovits E, Schiff E, Rosner Y, Toubi E, Kessel A, Ben Izhak O, Moskovitz B, Nativ O. [KIDNEY DISEASES IN NORTH ISRAEL ACCORDING TO KIDNEY BIOPSIES - BNAI-ZION MEDICAL CENTER 14 YEARS' EXPERIENCE]. Harefuah 2016; 155:537-541. [PMID: 28530079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
INTRODUCTION Little is known about the prevalence of kidney diseases according to renal biopsy in Israel. Since updated literature worldwide emphasizes changing etiologies of chronic kidney disease, it is crucial to research and define the epidemiology and pathology of kidney disease in Israel. Hereby, we introduce an original review of the prevalence of kidney diseases in our study population, which we believe reflects the prevalence of kidney diseases in the population of Israel. AIMS To investigate the prevalence of kidney diseases diagnosed by renal biopsy, according to age, gender, race and clinical symptoms. METHODS A total of 155 kidney biopsies were conducted in the years 2000-2014 in Bnai-Zion Medical Center in Haifa, according to formal accepted indications. Most of the biopsies (65%) were needle aspirations in a retroperitoneal approach, in which 90% were ultrasound guided and the rest computed tomography guided, while the other 35% of biopsies involved laparoscopic approaches. RESULTS The most common indications for kidney biopsy were nephrotic syndrome, nephritic syndrome and proteinuria (37.4%, 25.8% and 24.5%, respectively). Average glomeruli number per biopsy was 17.5 vs. 82.2 for needle aspiration and laparoscopic approach, respectively (statistically significant). The most common diagnosis was focal segmental glomerulosclerosis (FSGS), followed by chronic glomerulonephritis, IgA nephropathy, lupus nephritis, minimal change disease (MCD), membranous nephropathy and tubulointerstitial disease (20%, 11.5%, 11.5%, 10.1%, 9.5%, 8.1% and 6.1%, respectively). CONCLUSIONS FSGS was the most common diagnosis in patients presented with nephrotic syndrome or proteinuria, men, and patients above 60 years of age. Patients below 30 years of age were mainly diagnosed with IgA nephropathy. DISCUSSION In recent years, FSGS is becoming more prevalent compared with other chronic kidney disease especially in the older population. IgA nephropathy is still the most common diagnosis in young patients and in patients presented with hematuria. To the best of our knowledge, no data exists on the prevalence of kidney diseases in Israel, and our study is an important contribution to the epidemiological and clinical knowledge on the subject.
Collapse
Affiliation(s)
- Shimon Storch
- Nephrology and Hypertension Unit, Bnai-Zion Medical Center, Haifa
| | - Nadav Willner
- Department of Internal Medicine B, Bnai-Zion Medical Center, Haifa
| | - Aurora Toubi
- Ultrasonography Unit, Department of Radiology, Bnai-Zion Medical Center, Haifa
| | | | | | | | - Elinor Grushka
- Nephrology and Hypertension Unit, Bnai-Zion Medical Center, Haifa
| | - Majed Odeh
- Department of Internal Medicine A, Bnai-Zion Medical Center, Haifa
| | - Efrat Wolfovits
- Department of Internal Medicine C, Bnai-Zion Medical Center, Haifa
| | - Elad Schiff
- Department of Internal Medicine B, Bnai-Zion Medical Center, Haifa
| | - Yitzhak Rosner
- Department of Rheumatology, Bnai-Zion Medical Center, Haifa
| | - Elias Toubi
- Allergy and Clinical Immunology Unit, Bnai-Zion Medical Center, Haifa
| | - Aharon Kessel
- Allergy and Clinical Immunology Unit, Bnai-Zion Medical Center, Haifa
| | - Ofer Ben Izhak
- Department of Pathology, Rambam Health Care Campus, Haifa
| | | | - Ofer Nativ
- Department of Urology, Bnai-Zion Medical Center, Haifa
| |
Collapse
|
35
|
Kessel A, Graif Y, Vadasz Z, Schichter-Konfino V, Almog M, Cohen S, Teplitski V, Stein N, Baiardini I, Maurer M, Toubi E. Adaptation and Validation of the Israeli Version of the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL). Isr Med Assoc J 2016; 18:461-465. [PMID: 28471576] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
BACKGROUND Chronic urticaria (CU) is a common disabling disorder. The CU-Q2oL (Chronic Urticaria Quality of Life Questionnaire) is a specific questionnaire for evaluating quality of life in CU patients. It consists of 23 items divided into six quality-of-life dimensions. It was initially developed in Italy and later validated in other countries. OBJECTIVES To validate and adapt the CU-Q2oL to the Hebrew language in order to make it suitable for use in Israel. METHODS The CU-Q2oL questionnaire was translated to Hebrew. A group of 119 CU patients were asked to complete this version, in addition to the Dermatology Life Quality Index (DLQI) and Urticaria Activity Score (UAS) questionnaires. A factorial analysis was performed to identify CU-Q2oL subscales, internal consistency and convergent validity assessment, as well as factors determining quality-of-life scores. RESULTS The factor analysis identified six scales of the Israeli CU-Q2oL: (i) sleep and concentration, (ii) function and mental status, (iii) embarrassment and clothing limitations, (iv) itching, (v) eating behavior and medication side effects, and (vi) swelling, which accounted for 77% of the data variance. Five scales showed good internal consistency over 0.81. The mean ± SD score of CU-Q2oL in our patients with CIU was 41 ± 21.7. We found a strong positive correlation between the overall scores of CU-Q2oL and DLQI questionnaires (r = 0.8, P < 0.01). Additionally, we found a positive correlation between UAS and both CU-Q2oL and DLQI (r = 0.62, P < 0.01, and r = 0.53, P < 0.01, respectively). CONCLUSIONS This study demonstrates that the Israeli CU-Q2oL questionnaire is suitable for both clinical use and research in Israel.
Collapse
Affiliation(s)
- Aharon Kessel
- Division of Allergy and Clinical Immunology, Bnai Zion Medical Center, affiliated with Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
| | - Yael Graif
- Allergy and Immunology Clinic, Pulmonary Institute, Rabin Medical Center (Beilinson Campus), Petah Tikva, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Zahava Vadasz
- Division of Allergy and Clinical Immunology, Bnai Zion Medical Center, affiliated with Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
| | - Vered Schichter-Konfino
- Division of Allergy and Clinical Immunology, Bnai Zion Medical Center, affiliated with Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
| | - Meital Almog
- Division of Allergy and Clinical Immunology, Bnai Zion Medical Center, affiliated with Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
| | - Shai Cohen
- Division of Internal Medicine and, Carmel Medical Center, affiliated with Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
| | - Valery Teplitski
- Allergy and Immunology Clinic, Pulmonary Institute, Rabin Medical Center (Beilinson Campus), Petah Tikva, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Nili Stein
- Department of Community Medicine and Epidemiology, Carmel Medical Center, affiliated with Rappaport Faculty of Medicine, Technion- Israel Institute of Technology, Haifa, Israel
| | - Ilaria Baiardini
- Allergy
- Respiratory Diseases Clinic, DIMI, University of Genoa, IRCCS AOU San Martino-IST, Genoa, Italy
| | - Marcus Maurer
- Department of Dermatology and Allergy, Allergie-Centrum-Charité/ECARF, Charité-Universitätsmedizin, Berlin, Germany
| | - Elias Toubi
- Division of Allergy and Clinical Immunology, Bnai Zion Medical Center, affiliated with Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
| |
Collapse
|
36
|
Vadasz Z, Kessel A, Hershko AY, Maurer M, Toubi E. Seasonal Exacerbation of Asthma Is Frequently Associated with Recurrent Episodes of Acute Urticaria. Int Arch Allergy Immunol 2016; 169:263-6. [PMID: 27240837 DOI: 10.1159/000446183] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2016] [Accepted: 04/11/2016] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Asthma and urticaria are both partially mediated by an increased release of histamine from highly activated mast cells. They are pathophysiologically different, as mast cell degranulation in these 2 disorders results from different mechanisms. OBJECTIVE To assess the incidence of urticaria in patients with asthma, and of asthma in patients with chronic spontaneous urticaria (CSU). PATIENTS AND METHODS Over 1 year of follow-up, asthma patients (n = 110) were assessed for the incidence and characteristics of urticaria, and a link, if it existed, to seasonal exacerbations and the severity of asthma was traced. We also prospectively assessed CSU patients (n = 95) during the same period of time for the incidence of asthma. Healthy individuals (n = 100), serving as a control group, were also assessed. RESULTS Episodes of urticaria occurred in 26/110 asthma patients (23.6%), but in only 2/100 healthy control subjects (2%) (p < 0.0001). During the 1-year observation period, episodes of urticaria were significantly more frequent in asthma patients with positive skin-prick test reactions (mainly seasonal pollens), and consequently occurred mostly during seasonal asthma exacerbation, i.e. during acute episodes of urticaria. The incidence of asthma in CSU patients was recorded in 10.5% of the group, similar to that in the healthy control population. DISCUSSION Our study demonstrates, for the first time, that asthma patients frequently develop acute urticaria, mainly during seasonal exacerbations. In contrast, CSU patients do not show an increased incidence of asthma.
Collapse
Affiliation(s)
- Zahava Vadasz
- Division of Allergy and Clinical Immunology, Bnai Zion Medical Center, Technion, Haifa, Israel
| | | | | | | | | |
Collapse
|
37
|
Förg B, Schötz J, Süßmann F, Förster M, Krüger M, Ahn B, Okell WA, Wintersperger K, Zherebtsov S, Guggenmos A, Pervak V, Kessel A, Trushin SA, Azzeer AM, Stockman MI, Kim D, Krausz F, Hommelhoff P, Kling MF. Attosecond nanoscale near-field sampling. Nat Commun 2016; 7:11717. [PMID: 27241851 PMCID: PMC4895016 DOI: 10.1038/ncomms11717] [Citation(s) in RCA: 56] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2016] [Accepted: 04/24/2016] [Indexed: 12/04/2022] Open
Abstract
The promise of ultrafast light-field-driven electronic nanocircuits has stimulated the development of the new research field of attosecond nanophysics. An essential prerequisite for advancing this new area is the ability to characterize optical near fields from light interaction with nanostructures, with sub-cycle resolution. Here we experimentally demonstrate attosecond near-field retrieval for a tapered gold nanowire. By comparison of the results to those obtained from noble gas experiments and trajectory simulations, the spectral response of the nanotaper near field arising from laser excitation can be extracted. Photoemission from nanometre-scale structures offer a route toward ultrafast light-field-driven electronic nanocircuits. Here, the authors use attosecond streaking spectroscopy for nanoscale characterization of near-fields in the vicinity of tapered gold nanowires.
Collapse
Affiliation(s)
- B Förg
- Max Planck Institute of Quantum Optics, Hans-Kopfermann-Str. 1, D-85748 Garching, Germany.,Department of Physics, Ludwig-Maximilians-Universität München, Am Coulombwall 1, D-85748 Garching, Germany
| | - J Schötz
- Max Planck Institute of Quantum Optics, Hans-Kopfermann-Str. 1, D-85748 Garching, Germany.,Department of Physics, Ludwig-Maximilians-Universität München, Am Coulombwall 1, D-85748 Garching, Germany
| | - F Süßmann
- Max Planck Institute of Quantum Optics, Hans-Kopfermann-Str. 1, D-85748 Garching, Germany.,Department of Physics, Ludwig-Maximilians-Universität München, Am Coulombwall 1, D-85748 Garching, Germany
| | - M Förster
- Max Planck Institute of Quantum Optics, Hans-Kopfermann-Str. 1, D-85748 Garching, Germany.,Department of Physics, Friedrich-Alexander-Universität Erlangen-Nürnberg, Staudtstraße 1, D-91058 Erlangen, Germany
| | - M Krüger
- Max Planck Institute of Quantum Optics, Hans-Kopfermann-Str. 1, D-85748 Garching, Germany.,Department of Physics, Friedrich-Alexander-Universität Erlangen-Nürnberg, Staudtstraße 1, D-91058 Erlangen, Germany
| | - B Ahn
- Department of Physics, CASTECH, POSTECH, Pohang, Kyungbuk 790-784, Republic of Korea.,Max Planck Center for Attosecond Science, Pohang, Kyungbuk 790-784, Republic of Korea
| | - W A Okell
- Max Planck Institute of Quantum Optics, Hans-Kopfermann-Str. 1, D-85748 Garching, Germany
| | - K Wintersperger
- Max Planck Institute of Quantum Optics, Hans-Kopfermann-Str. 1, D-85748 Garching, Germany
| | - S Zherebtsov
- Max Planck Institute of Quantum Optics, Hans-Kopfermann-Str. 1, D-85748 Garching, Germany.,Department of Physics, Ludwig-Maximilians-Universität München, Am Coulombwall 1, D-85748 Garching, Germany
| | - A Guggenmos
- Max Planck Institute of Quantum Optics, Hans-Kopfermann-Str. 1, D-85748 Garching, Germany.,Department of Physics, Ludwig-Maximilians-Universität München, Am Coulombwall 1, D-85748 Garching, Germany
| | - V Pervak
- Department of Physics, Ludwig-Maximilians-Universität München, Am Coulombwall 1, D-85748 Garching, Germany
| | - A Kessel
- Max Planck Institute of Quantum Optics, Hans-Kopfermann-Str. 1, D-85748 Garching, Germany
| | - S A Trushin
- Max Planck Institute of Quantum Optics, Hans-Kopfermann-Str. 1, D-85748 Garching, Germany
| | - A M Azzeer
- Attosecond Science Laboratory, King-Saud University, Riyadh 11451, Saudi Arabia
| | - M I Stockman
- Max Planck Institute of Quantum Optics, Hans-Kopfermann-Str. 1, D-85748 Garching, Germany.,Department of Physics and Astronomy, Georgia State University, Atlanta, Georgia 30303, USA
| | - D Kim
- Department of Physics, CASTECH, POSTECH, Pohang, Kyungbuk 790-784, Republic of Korea.,Max Planck Center for Attosecond Science, Pohang, Kyungbuk 790-784, Republic of Korea
| | - F Krausz
- Max Planck Institute of Quantum Optics, Hans-Kopfermann-Str. 1, D-85748 Garching, Germany.,Department of Physics, Ludwig-Maximilians-Universität München, Am Coulombwall 1, D-85748 Garching, Germany
| | - P Hommelhoff
- Max Planck Institute of Quantum Optics, Hans-Kopfermann-Str. 1, D-85748 Garching, Germany.,Department of Physics, Friedrich-Alexander-Universität Erlangen-Nürnberg, Staudtstraße 1, D-91058 Erlangen, Germany
| | - M F Kling
- Max Planck Institute of Quantum Optics, Hans-Kopfermann-Str. 1, D-85748 Garching, Germany.,Department of Physics, Ludwig-Maximilians-Universität München, Am Coulombwall 1, D-85748 Garching, Germany
| |
Collapse
|
38
|
Abstract
INTRODUCTION An unprecedented global effort has been required to tackle the Ebola outbreak in West Africa. In this paper, we describe the contribution of Public Health England (PHE) in West Africa and the UK. SOURCES OF DATA Public Health England AREAS OF AGREEMENT The epidemic has been a humanitarian crisis for the three worst affected countries. PHE contributions have included expertise in outbreak control and microbiology services in West Africa, and UK preparedness for an imported case. AREAS OF CONTROVERSY National and international systems require change to enhance the response to the next international public health crisis. GROWING POINTS Legacy planning following the epidemic will be crucial, supporting the recovery of the health and public health systems in West Africa and ensuring that the knowledge gained during this outbreak is put to best use. AREAS TIMELY FOR DEVELOPING RESEARCH Ongoing PHE-associated research includes efforts to understand the pathogenicity of Ebola virus disease, improve diagnostic capability, explore therapeutic options and develop new vaccines.
Collapse
Affiliation(s)
- R Moll
- Public Health England, Wellington House, 133-155 Waterloo Road, London SE1 8UG, UK
| | - S Reece
- Public Health England, Wellington House, 133-155 Waterloo Road, London SE1 8UG, UK
| | - P Cosford
- Public Health England, Wellington House, 133-155 Waterloo Road, London SE1 8UG, UK
| | - A Kessel
- Public Health England, Wellington House, 133-155 Waterloo Road, London SE1 8UG, UK
| |
Collapse
|
39
|
Lidar M, Livneh A, Zvi IB, Cohen R, Berkun Y, Hashkes P, Peleg H, Kessel A, Almog R, Kali L, Slobodin G, Rozenbaum M, Shinar Y. The clinical phenotype of Israeli patients with Q703K mutation in the NLRP3 gene. Pediatr Rheumatol Online J 2015. [PMCID: PMC4596999 DOI: 10.1186/1546-0096-13-s1-p42] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
40
|
Kessel A, Odeh M, Rofe A. [93 YEARS OF CLINICAL EMPATHY, STATE-OF-THE-ART MEDICINE AND RESEARCH EXCELLENCE]. Harefuah 2015; 154:750-806. [PMID: 26897773] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
This issue of Harefuah is devoted to articles and reviews written by the medical staff of Bnai Zion Medical Center in Haifa. Celebrating 93 years since its inception, Bnai Zion Medical Center is home to the oldest public hospital in Haifa, and a founding affiliate of the Technion's Faculty of Medicine. Known for its centers of excellence and the impactful clinical and basic research developed, the hospital has a reputation for state-of-the-art medicine, both conventional and complementary. Bnai Zion prides itself as an innovation leader in medical and nursing education, with its staff's empathetic and personalized approach to patient care, and the center's dedication to applying emotional intelligence to medicine.
Collapse
|
41
|
Slobodin G, Slobodin B, Rimar D, Peri R, Kessel A, Toubi E, Rosner I, Odeh M. Production of bone formation-regulating factors by osteoclasts in vitro does not correlate with the radiographic disease progression in patients with ankylosing spondylitis. Joint Bone Spine 2015; 83:468-9. [PMID: 26453099 DOI: 10.1016/j.jbspin.2015.06.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2015] [Accepted: 06/05/2015] [Indexed: 11/18/2022]
Affiliation(s)
- Gleb Slobodin
- Internal Medicine A, Bnai Zion Medical Center, 47, Golomb Street, Haifa 31048, Israel; Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa 31048, Israel.
| | - Boris Slobodin
- Division of Stress Response, Netherlands Cancer Institute, Amsterdam 1006, The Netherlands
| | - Doron Rimar
- Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa 31048, Israel; Rhematology, Bnai Zion Medical Center, Haifa 31048, Israel
| | - Regina Peri
- Immunology, Bnai Zion Medical Center, Haifa 31048, Israel
| | - Aharon Kessel
- Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa 31048, Israel; Immunology, Bnai Zion Medical Center, Haifa 31048, Israel
| | - Elias Toubi
- Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa 31048, Israel; Immunology, Bnai Zion Medical Center, Haifa 31048, Israel
| | - Itzhak Rosner
- Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa 31048, Israel; Rhematology, Bnai Zion Medical Center, Haifa 31048, Israel
| | - Majed Odeh
- Internal Medicine A, Bnai Zion Medical Center, 47, Golomb Street, Haifa 31048, Israel; Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa 31048, Israel
| |
Collapse
|
42
|
Fleischer DM, Sicherer S, Greenhawt M, Campbell D, Chan E, Muraro A, Halken S, Katz Y, Ebisawa M, Eichenfield L, Sampson H, Lack G, Du Toit G, Roberts G, Bahnson H, Feeney M, Hourihane J, Spergel J, Young M, As'aad A, Allen K, Prescott S, Kapur S, Saito H, Agache I, Akdis CA, Arshad H, Beyer K, Dubois A, Eigenmann P, Fernandez-Rivas M, Grimshaw K, Hoffman-Sommergruber K, Host A, Lau S, O'Mahony L, Mills C, Papadopoulos N, Venter C, Agmon-Levin N, Kessel A, Antaya R, Drolet B, Rosenwasser L. Consensus communication on early peanut introduction and the prevention of peanut allergy in high-risk infants. Allergy 2015; 70:1193-5. [PMID: 26148305 DOI: 10.1111/all.12687] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Affiliation(s)
| | | | | | - M. Greenhawt
- American College of Allergy, Asthma & Immunology (ACAAI)
| | - D. Campbell
- Australasian Society of Clinical Immunology and Allergy (ASCIA)
| | - E. Chan
- Canadian Society of Allergy and Clinical Immunology (CSACI)
| | - A. Muraro
- European Academy of Allergy and Clinical Immunology (EAACI)
| | - S. Halken
- European Academy of Allergy and Clinical Immunology (EAACI)
| | - Y. Katz
- Israel Association of Allergy and Clinical Immunology (ISACI)
| | | | | | | | - G. Lack
- World Allergy Organization (WAO)
| | - G. Du Toit
- European Academy of Allergy and Clinical Immunology (EAACI)
| | - G. Roberts
- European Academy of Allergy and Clinical Immunology (EAACI)
| | | | | | - J. Hourihane
- American Academy of Allergy, Asthma & Immunology (AAAAI)
| | - J. Spergel
- American Academy of Allergy, Asthma & Immunology (AAAAI)
| | - M. Young
- American Academy of Allergy, Asthma & Immunology (AAAAI)
| | - A. As'aad
- American College of Allergy, Asthma & Immunology (ACAAI)
| | - K. Allen
- Australasian Society of Clinical Immunology and Allergy (ASCIA)
| | - S. Prescott
- Australasian Society of Clinical Immunology and Allergy (ASCIA)
| | - S. Kapur
- Canadian Society of Allergy and Clinical Immunology (CSACI)
| | - H. Saito
- Japanese Society for Allergology (JSA)
| | - I. Agache
- European Academy of Allergy and Clinical Immunology (EAACI)
| | - C. A. Akdis
- European Academy of Allergy and Clinical Immunology (EAACI)
| | - H. Arshad
- European Academy of Allergy and Clinical Immunology (EAACI)
| | - K. Beyer
- European Academy of Allergy and Clinical Immunology (EAACI)
| | - A. Dubois
- European Academy of Allergy and Clinical Immunology (EAACI)
| | - P. Eigenmann
- European Academy of Allergy and Clinical Immunology (EAACI)
| | | | - K. Grimshaw
- European Academy of Allergy and Clinical Immunology (EAACI)
| | | | - A. Host
- European Academy of Allergy and Clinical Immunology (EAACI)
| | - S. Lau
- European Academy of Allergy and Clinical Immunology (EAACI)
| | - L. O'Mahony
- European Academy of Allergy and Clinical Immunology (EAACI)
| | - C. Mills
- European Academy of Allergy and Clinical Immunology (EAACI)
| | | | - C. Venter
- European Academy of Allergy and Clinical Immunology (EAACI)
| | - N. Agmon-Levin
- Israel Association of Allergy and Clinical Immunology (ISACI)
| | - A. Kessel
- Israel Association of Allergy and Clinical Immunology (ISACI)
| | - R. Antaya
- Society for Pediatric Dermatology (SPD)
| | - B. Drolet
- Society for Pediatric Dermatology (SPD)
| | | | | | | |
Collapse
|
43
|
Süßmann F, Seiffert L, Zherebtsov S, Mondes V, Stierle J, Arbeiter M, Plenge J, Rupp P, Peltz C, Kessel A, Trushin SA, Ahn B, Kim D, Graf C, Rühl E, Kling MF, Fennel T. Field propagation-induced directionality of carrier-envelope phase-controlled photoemission from nanospheres. Nat Commun 2015; 6:7944. [PMID: 26264422 PMCID: PMC4557130 DOI: 10.1038/ncomms8944] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2015] [Accepted: 06/27/2015] [Indexed: 12/12/2022] Open
Abstract
Near-fields of non-resonantly laser-excited nanostructures enable strong localization of ultrashort light fields and have opened novel routes to fundamentally modify and control electronic strong-field processes. Harnessing spatiotemporally tunable near-fields for the steering of sub-cycle electron dynamics may enable ultrafast optoelectronic devices and unprecedented control in the generation of attosecond electron and photon pulses. Here we utilize unsupported sub-wavelength dielectric nanospheres to generate near-fields with adjustable structure and study the resulting strong-field dynamics via photoelectron imaging. We demonstrate field propagation-induced tunability of the emission direction of fast recollision electrons up to a regime, where nonlinear charge interaction effects become dominant in the acceleration process. Our analysis supports that the timing of the recollision process remains controllable with attosecond resolution by the carrier-envelope phase, indicating the possibility to expand near-field-mediated control far into the realm of high-field phenomena. The localized enhancement of laser light in optical near-fields of nanostructures enables the steering of ultrafast electronic motion. Here, the authors employ field propagation in nanospheres to obtain directional tunability and attosecond control of near-field-induced strong-field photoemission.
Collapse
Affiliation(s)
- F Süßmann
- Max-Planck-Institut für Quantenoptik, D-85748 Garching, Germany.,Physics Department, Ludwig-Maximilians-Universität München, D-85748 Garching, Germany
| | - L Seiffert
- Institut für Physik, Universität Rostock, D-18051 Rostock, Germany
| | - S Zherebtsov
- Max-Planck-Institut für Quantenoptik, D-85748 Garching, Germany.,Physics Department, Ludwig-Maximilians-Universität München, D-85748 Garching, Germany
| | - V Mondes
- Physical Chemistry, Freie Universität Berlin, Takustr. 3, D-14195 Berlin, Germany
| | - J Stierle
- Max-Planck-Institut für Quantenoptik, D-85748 Garching, Germany
| | - M Arbeiter
- Institut für Physik, Universität Rostock, D-18051 Rostock, Germany
| | - J Plenge
- Physical Chemistry, Freie Universität Berlin, Takustr. 3, D-14195 Berlin, Germany
| | - P Rupp
- Max-Planck-Institut für Quantenoptik, D-85748 Garching, Germany.,Physics Department, Ludwig-Maximilians-Universität München, D-85748 Garching, Germany
| | - C Peltz
- Institut für Physik, Universität Rostock, D-18051 Rostock, Germany
| | - A Kessel
- Max-Planck-Institut für Quantenoptik, D-85748 Garching, Germany
| | - S A Trushin
- Max-Planck-Institut für Quantenoptik, D-85748 Garching, Germany
| | - B Ahn
- Department of Physics, Center for Attosecond Science and Technology, Pohang University of Science and Technology, Pohang 790-784, South Korea.,Max Planck Center for Attosecond Science, Max Planck POSTECH/KOREA Res. Init., Pohang 790-784, South Korea
| | - D Kim
- Department of Physics, Center for Attosecond Science and Technology, Pohang University of Science and Technology, Pohang 790-784, South Korea.,Max Planck Center for Attosecond Science, Max Planck POSTECH/KOREA Res. Init., Pohang 790-784, South Korea
| | - C Graf
- Physical Chemistry, Freie Universität Berlin, Takustr. 3, D-14195 Berlin, Germany
| | - E Rühl
- Physical Chemistry, Freie Universität Berlin, Takustr. 3, D-14195 Berlin, Germany
| | - M F Kling
- Max-Planck-Institut für Quantenoptik, D-85748 Garching, Germany.,Physics Department, Ludwig-Maximilians-Universität München, D-85748 Garching, Germany.,Department of Physics, Center for Attosecond Science and Technology, Pohang University of Science and Technology, Pohang 790-784, South Korea.,J.R. Macdonald Laboratory, Physics Department, Kansas-State University, Manhattan, Kansas, USA
| | - T Fennel
- Institut für Physik, Universität Rostock, D-18051 Rostock, Germany
| |
Collapse
|
44
|
Abu Raya B, Srugo I, Bamberger E, Kessel A. The avidity of pertussis antibodies following gestational acellular pertussis immunization: Reply to Maertens. Vaccine 2015; 33:5490-5491. [PMID: 26071193 DOI: 10.1016/j.vaccine.2015.05.090] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2015] [Accepted: 05/22/2015] [Indexed: 11/17/2022]
Affiliation(s)
- Bahaa Abu Raya
- Department of Pediatrics, Bnai Zion Medical Center, Golomb St. 47, Haifa 31048, Israel; The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Efron St. 1, Haifa 31096, Israel.
| | - Isaac Srugo
- Department of Pediatrics, Bnai Zion Medical Center, Golomb St. 47, Haifa 31048, Israel; The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Efron St. 1, Haifa 31096, Israel; Clinical Microbiology Laboratory, Bnai Zion Medical Center, Golomb St. 47, Haifa 31048, Israel
| | - Ellen Bamberger
- The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Efron St. 1, Haifa 31096, Israel; Clinical Microbiology Laboratory, Bnai Zion Medical Center, Golomb St. 47, Haifa 31048, Israel
| | - Aharon Kessel
- The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Efron St. 1, Haifa 31096, Israel; Division of Allergy and Clinical Immunology, Bnai Zion Medical Center, Golomb St. 47, Haifa 31048, Israel
| |
Collapse
|
45
|
Abu Raya B, Srugo I, Kessel A, Peterman M, Vaknin A, Bamberger E. The Decline of Pertussis-Specific Antibodies After Tetanus, Diphtheria, and Acellular Pertussis Immunization in Late Pregnancy. J Infect Dis 2015; 212:1869-73. [PMID: 26160743 DOI: 10.1093/infdis/jiv324] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2015] [Accepted: 05/30/2015] [Indexed: 11/12/2022] Open
Abstract
We prospectively measured pertussis-specific antibodies 9-15 months after delivery in women immunized with tetanus, diphtheria, and acellular pertussis (Tdap) after the 20th week of their recent pregnancy. The Tdap-immunized women (n = 38) exhibited a decline in geometric mean concentrations between their peripartum and follow-up levels for immunoglobulin G to pertussis toxin (21.48 [95% confidence interval, 12.51-36.89] vs 11.72 [7.09-19.37] IU/mL];); filamentous hemagglutinin (185.95 [157.93-218.94] vs 140.33 IU/mL [113.46-173.57] IU/mL); and pertactin (171.52 [120.73-243.67] vs 83.74 [60.58-115.75] IU/mL) (all P < .001). For women immunized with Tdap during late pregnancy, pertussis-specific immunoglobulin G levels decreased significantly 9-15 months after delivery.
Collapse
Affiliation(s)
- Bahaa Abu Raya
- Department of Pediatrics The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa
| | - Isaac Srugo
- Department of Pediatrics Clinical Microbiology Laboratory The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa
| | - Aharon Kessel
- Division of Allergy and Clinical Immunology, Bnai Zion Medical Center The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa
| | | | - Avraham Vaknin
- The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa
| | - Ellen Bamberger
- Clinical Microbiology Laboratory The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa
| |
Collapse
|
46
|
Schichter-Konfino V, Almog M, Bamberger E, Berkowitz D, Kessel A. The significance of allergic contact urticaria to milk in children with cow's milk allergy. Pediatr Allergy Immunol 2015; 26:218-222. [PMID: 25775957 DOI: 10.1111/pai.12375] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 03/12/2015] [Indexed: 02/04/2023]
Abstract
BACKGROUND Cow's milk allergy (CMA) is the most common food allergy in infancy. Food allergy is generally triggered through ingestion, but can also be triggered through skin contact. We investigated the incidence and the clinical significance of cow's milk protein (CMP)-induced contact urticaria in individuals with CMA with and without atopic dermatitis (AD). METHODS A total of 157 children of whom 133 were diagnosed with CMA were participated. The study was based on observational data gathered in the course of patient care, including a skin prick test and a 'finger test', in which cow's milk is applied on the cheek by a physician's finger to detect contact urticaria. RESULTS Eighty nine of 133 patients (66.9%) had IgE-mediated CMA. Forty of these 89 (44.9%) tested positive in the finger test. Family atopy was higher in those with positive contact urticaria [21/40 (52.5%) vs. 14/49 (28.5%), p = 0.029]. Patients with positive vs. negative CMP contact urticaria had higher incidence of multiple food allergies [20 of 40 (50%) vs. 7/49 (14.3%), p < 0.004]. IgE-mediated CMA patients with AD had statistically higher CMP allergic contact urticaria compared to patients without AD [71% (15/21) vs. 37% (25/68), p = 0.0064]. Children with non-IgE milk allergy and healthy control group did not have contact urticaria to CMP. CONCLUSION CMP contact urticaria exists only in patients with IgE-mediated CMA. A 'finger test' to CMP should be part of the evaluation of CMA patients, and positivity suggests the potential for multiple food allergies, especially to sesame and egg.
Collapse
Affiliation(s)
- Vered Schichter-Konfino
- Division of Allergy & Clinical Immunology, Bnai-Zion Medical Center, Rappaport Faculty of Medicine, Technion, Haifa, Israel
| | - Meital Almog
- Division of Allergy & Clinical Immunology, Bnai-Zion Medical Center, Rappaport Faculty of Medicine, Technion, Haifa, Israel
| | - Ellen Bamberger
- Pediatric Department, Bnai-Zion Medical Center, Rappaport Faculty of Medicine, Technion, Haifa, Israel
| | - Drora Berkowitz
- Pediatric Gastroenterology Unit, Bnai-Zion Medical Center, Rappaport Faculty of Medicine, Technion, Haifa, Israel
| | - Aharon Kessel
- Division of Allergy & Clinical Immunology, Bnai-Zion Medical Center, Rappaport Faculty of Medicine, Technion, Haifa, Israel
| |
Collapse
|
47
|
Schichter-Konfino V, Halasz K, Grushko G, Snir A, Haj T, Vadasz Z, Kessel A, Potasman I, Toubi E. Interferon-gamma-release assay prevents unnecessary tuberculosis therapy. Isr Med Assoc J 2015; 17:223-226. [PMID: 26040047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
BACKGROUND The mass influx of immigrants from tuberculosis-endemic countries into Israel was followed by a considerable increase in the incidence of tuberculosis (TB). All contacts of active TB patients are obliged to be screened by tuberculin skin tests (TST) and, if found positive, prophylactic treatment is considered. OBJECTIVES To assess the utility of interferon-gamma (IFNγ)-release assay with a prolonged follow-up in preventing unnecessary anti-TB therapy in individuals with suspected false positive results. METHODS Between 2008 and 2012 the QuantiFERON TB gold-in-tube test (QFT-G) was performed in 278 sequential individuals who were mostly TST-positive and/or were in contact with an active TB patient. In all, whole blood was examined by the IFNγ-release assay. We correlated the TST diameter with the QFT-G assay and followed those patients with a negative assay. RESULTS The QFT-G test was positive in only 72 (42%) of all 171 TST-positive individuals. There was no correlation between the diameter of TST and QFT-G positivity. Follow-up over 5 years was available in 128 (62%) of all QFT-G-negative individuals. All remained well and none developed active TB. CONCLUSIONS A negative QFT-G test may obviate the need for anti-TB therapy in more than half of those with a positive TST.
Collapse
|
48
|
Li H, Mignolet B, Wachter G, Skruszewicz S, Zherebtsov S, Süssmann F, Kessel A, Trushin SA, Kling NG, Kübel M, Ahn B, Kim D, Ben-Itzhak I, Cocke CL, Fennel T, Tiggesbäumker J, Meiwes-Broer KH, Lemell C, Burgdörfer J, Levine RD, Remacle F, Kling MF. Coherent electronic wave packet motion in C(60) controlled by the waveform and polarization of few-cycle laser fields. Phys Rev Lett 2015; 114:123004. [PMID: 25860740 DOI: 10.1103/physrevlett.114.123004] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/12/2014] [Indexed: 05/20/2023]
Abstract
Strong laser fields can be used to trigger an ultrafast molecular response that involves electronic excitation and ionization dynamics. Here, we report on the experimental control of the spatial localization of the electronic excitation in the C_{60} fullerene exerted by an intense few-cycle (4 fs) pulse at 720 nm. The control is achieved by tailoring the carrier-envelope phase and the polarization of the laser pulse. We find that the maxima and minima of the photoemission-asymmetry parameter along the laser-polarization axis are synchronized with the localization of the coherent electronic wave packet at around the time of ionization.
Collapse
Affiliation(s)
- H Li
- Max Planck Institute of Quantum Optics, Garching D-85748, Germany
- Department of Physics, Ludwig-Maximilians-Universität München, Garching D-85748, Germany
- J.R. MacDonald Laboratory, Physics Department, Kansas State University, Manhattan, Kansas 66506, USA
| | - B Mignolet
- Department of Chemistry, University of Liège, Liège B-4000, Belgium
| | - G Wachter
- Institute for Theoretical Physics, Vienna University of Technology, Vienna A-1040, Austria
| | - S Skruszewicz
- Institute of Physics, Universität Rostock, Rostock D-18051, Germany
| | - S Zherebtsov
- Max Planck Institute of Quantum Optics, Garching D-85748, Germany
- Department of Physics, Ludwig-Maximilians-Universität München, Garching D-85748, Germany
| | - F Süssmann
- Max Planck Institute of Quantum Optics, Garching D-85748, Germany
- Department of Physics, Ludwig-Maximilians-Universität München, Garching D-85748, Germany
| | - A Kessel
- Max Planck Institute of Quantum Optics, Garching D-85748, Germany
| | - S A Trushin
- Max Planck Institute of Quantum Optics, Garching D-85748, Germany
| | - Nora G Kling
- Department of Physics, Ludwig-Maximilians-Universität München, Garching D-85748, Germany
- J.R. MacDonald Laboratory, Physics Department, Kansas State University, Manhattan, Kansas 66506, USA
| | - M Kübel
- Max Planck Institute of Quantum Optics, Garching D-85748, Germany
- Department of Physics, Ludwig-Maximilians-Universität München, Garching D-85748, Germany
| | - B Ahn
- Max Planck Institute of Quantum Optics, Garching D-85748, Germany
- Physics Department, CASTECH, POSTECH, Pohang, Kyungbuk 790-784, Republic of Korea
- Max Planck Center for Attosecond Science, Max Planck POSTECH/KOREA Research Initiative, Pohang 790-784, Republic of Korea
| | - D Kim
- Physics Department, CASTECH, POSTECH, Pohang, Kyungbuk 790-784, Republic of Korea
- Max Planck Center for Attosecond Science, Max Planck POSTECH/KOREA Research Initiative, Pohang 790-784, Republic of Korea
| | - I Ben-Itzhak
- J.R. MacDonald Laboratory, Physics Department, Kansas State University, Manhattan, Kansas 66506, USA
| | - C L Cocke
- J.R. MacDonald Laboratory, Physics Department, Kansas State University, Manhattan, Kansas 66506, USA
| | - T Fennel
- Institute of Physics, Universität Rostock, Rostock D-18051, Germany
| | - J Tiggesbäumker
- Institute of Physics, Universität Rostock, Rostock D-18051, Germany
| | - K-H Meiwes-Broer
- Institute of Physics, Universität Rostock, Rostock D-18051, Germany
| | - C Lemell
- Institute for Theoretical Physics, Vienna University of Technology, Vienna A-1040, Austria
| | - J Burgdörfer
- Institute for Theoretical Physics, Vienna University of Technology, Vienna A-1040, Austria
- Institute of Nuclear Research of the Hungarian Academy of Sciences (ATOMKI), Debrecen H-4001, Hungary
| | - R D Levine
- Fritz Haber Center for Molecular Dynamics, Hebrew University of Jerusalem, Jerusalem 91904, Israel
- Department of Chemistry and Biochemistry, University of California Los Angeles, Los Angeles, California 90095, USA
| | - F Remacle
- Department of Chemistry, University of Liège, Liège B-4000, Belgium
| | - M F Kling
- Max Planck Institute of Quantum Optics, Garching D-85748, Germany
- Department of Physics, Ludwig-Maximilians-Universität München, Garching D-85748, Germany
- J.R. MacDonald Laboratory, Physics Department, Kansas State University, Manhattan, Kansas 66506, USA
| |
Collapse
|
49
|
Abu Raya B, Bamberger E, Almog M, Peri R, Srugo I, Kessel A. Immunization of pregnant women against pertussis: the effect of timing on antibody avidity. Vaccine 2015; 33:1948-52. [PMID: 25744227 DOI: 10.1016/j.vaccine.2015.02.059] [Citation(s) in RCA: 51] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2014] [Revised: 01/26/2015] [Accepted: 02/20/2015] [Indexed: 02/06/2023]
Abstract
BACKGROUND The Centers for Disease Control and Prevention recommend tetanus-diphteria-acellular pertussis (Tdap) immunization during pregnancy, preferably at 27-36 weeks gestation. AIMS First, to assess the relative avidity index (RAI) of umbilical cord immunoglobulin G (IgG) to pertussis toxin (PT) for newborns of women immunized with Tdap during late pregnancy as compared to unimmunized women. Second, to assess whether there is a preferential period of gestational Tdap immunization that provides the highest RAI of umbilical cord IgG to PT. METHODS RAI of IgG to PT was assessed via an adapted ELISA using NH4SCN as a dissociating agent. RESULTS We found that newborns of women immunized with Tdap during late pregnancy (n=52) had higher mean RAI of umbilical cord IgG to PT than those of unimmunized women (n=8), 73.77%±12.08 (95% CI, 70.41-77.13) vs. 50.23%±21.32 (95% CI, 32.41-68.06), p<0.001. Further, the RAI of umbilical cord IgG to PT was significantly higher in newborns of women immunized at 27-30(+6) weeks gestation (n=20) when compared with newborns of women immunized at 31-36 weeks (n=22) and >36 weeks (n=7), 79.53%±5.61 (95% CI, 76.91-82.16) vs. 71.56%±12.58 (95% CI, 65.98-77.14) vs. 63.93%±17.98 (95% CI, 47.31-80.56), p<0.03. CONCLUSION Gestational Tdap immunization between 27 and 30(+6) weeks resulted in the highest avidity of IgG to PT conveyed at delivery as compared with immunization beyond 31 weeks gestation. Future studies should be conducted to confirm our findings to optimize pertussis-controlling strategies.
Collapse
Affiliation(s)
- Bahaa Abu Raya
- Department of Pediatrics, Bnai Zion Medical Center, Golomb St. 47, Haifa 31048, Israel; The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Efron St. 1, Haifa 31096, Israel.
| | - Ellen Bamberger
- The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Efron St. 1, Haifa 31096, Israel; Clinical Microbiology Laboratory, Bnai Zion Medical Center, Golomb St. 47, Haifa 31048, Israel
| | - Meital Almog
- The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Efron St. 1, Haifa 31096, Israel; Division of Allergy and Clinical Immunology, Bnai Zion Medical Center, Golomb St. 47, Haifa 31048, Israel
| | - Regina Peri
- Division of Allergy and Clinical Immunology, Bnai Zion Medical Center, Golomb St. 47, Haifa 31048, Israel
| | - Isaac Srugo
- Department of Pediatrics, Bnai Zion Medical Center, Golomb St. 47, Haifa 31048, Israel; The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Efron St. 1, Haifa 31096, Israel; Clinical Microbiology Laboratory, Bnai Zion Medical Center, Golomb St. 47, Haifa 31048, Israel
| | - Aharon Kessel
- The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Efron St. 1, Haifa 31096, Israel; Division of Allergy and Clinical Immunology, Bnai Zion Medical Center, Golomb St. 47, Haifa 31048, Israel
| |
Collapse
|
50
|
Ovadia A, Kessel A, Leshinsky-Silver E, Dalal I. A novel STAT3 mutation in a patient with hyper-immunoglobulin E syndrome. Isr Med Assoc J 2015; 17:62-63. [PMID: 25739182] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
|